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 palavras-chave 
 
Farmacovigilância, reação adversa, gestão do risco, 
monitorização de medicamentos. 
resumo 
 
 
Este relatório é o culminar de 12 meses de constante 
aprendizagem na Direção de Gestão de Risco do Medicamentos. 
 
Este estágio decorreu nas áreas da Minimização do Risco e da 
Monitorização de Segurança de Medicamentos de Uso Humano. 
 
A minimização do risco centra-se em assegurar a segurança dos 
medicamentos através da monitorização e avaliação de 
segurança dos medicamentos a implementação de medidas de 
segurança adequadas aos riscos identificados, tais como a 
avaliação de materiais educacionais, implementação de 
alterações de segurança ao Resumo das Características dos 
Medicamentos e Folheto Informativo, acompanhamento e 
implementação de medidas urgentes de segurança e 
comunicação e divulgação de informação de segurança através 
da validação das Direct Healthcare Professional Communications 
DHPC, elaboração de Circulares Informativas e artigos para o 
Boletim de Farmacovigilância. Incluiu ainda as actividades de 
gestão dos Relatórios Periódicos de Segurança e de gestão do 
sistema de alertas europeu.  
 
A área de monitorização de segurança centra-se em recolher e 
avaliar as notificações de casos de reações adversas recolhidas 
no âmbito do sistema nacional de farmacovigilância. Tem ainda a 
obrigação de enviar essa informação para os parceiros internos 
e externos e gerir todo processo de gestão de sinal.  
 
O estágio em ambas as áreas mencionadas permitiu-me adquirir 
competências indispensáveis para o meu percurso profissional e 
permitiu-me compreender como funciona uma Autoridade 
Nacional do Medicamento e a sua interação com a indústria 
farmacêutica, com os profissionais de saúde e com os doentes.  
 
 
 
 
 keywords 
 
Pharmacovigilance, adverse reaction, risk management, drug 
monitoring. 
 
abstract 
 
This report is the result of 12 months of constant learning at 
Directorate of Risk Management for Medicines. 
 
This internship was held in the areas of Risk Management and 
Medicines Monitoring. 
 
The risk management focuses on ensuring the safety monitoring 
of medicines through the monitoring and safety evaluation of 
medicines and implementation of safety measures appropriate to 
the identified risks, such as the evaluation of educational 
materials, implementation of safety variations to the Summary of 
Product Characteristics and Package Leaflet, monitoring and 
implementation of urgent safety measures and communications 
and dissemination of safety information through the validation of 
DHPC, press releases and articles for the Pharmacovigilance 
Bulletin. It also includes the activities of Periodic Safety Update 
Reports management and management of European Alerts.  
 
The area of medicines monitoring aims to gather and evaluate the 
adverse reactions collected within the national pharmacovigilance 
system and disseminate safety information required for safe use 
of medicines. It has also the responsibility to send that information 
to internal and external partners and the manage signal 
detections and evaluation.  
 
The internship in both areas allowed me to acquire skills 
necessary for my career and allowed to understand how a 
National Competent Authority functions e and how interacts with 
the pharmaceutical industry, healthcare professionals and 
patients.  
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1. Introduction  
 
This document is a description of the 12-month training at Autoridade Nacional do Medicamento e Produtos 
de Saúde, I.P. (INFARMED, I.P.), in the Directorate of Risk Management for Medicines. This internship 
allowed me to develop some of the knowledge acquired in the degree and master through applying it in 
practical work.  
The pharmacovigilance has an important role in the protection of the public health and in the continuous 
evaluation of the medicines’ risks and benefits. This science went through several modifications in the last 
few years, with the creation of new legislation and recognition of its importance in the protection of public 
health. The importance of pharmacovigilance is due to the fact that when a medicine is in the phase of 
clinical research, it is evaluated in a controlled environment, where the volunteers are chosen according to 
certain requirements and narrow criteria (1). Once a medicine is on the market, it is available for the 
majority of the population and more precisely to certain special groups such as children, pregnant women, 
elderly and also in patients with concomitant diseases and medicinal products, therefore there will be new 
scientific data, including new and rare adverse effects that were not detected during clinical trials (1). 
Although the pharmacovigilance is present in the early stages of drug development, it assumes a major role 
during the post-approval phase, where the safety profile of the medicine will be in constant re-analysis. 
Therefore it is necessary that the new medicines may be monitored for their effectiveness and safety under 
real-life conditions post release. Thus the ultimate purpose of pharmacovigilance is to minimise, in practice, 
the potential for harm that is associated with all medicines (1). 
To improve patient safety and public health, the pharmacovigilance legislation came into force in July 2012. 
It strengthens and rationalises the system for monitoring the safety of medicines on the European market. 
(2)  
 
The main objectives of pharmacovigilance are (3): 
 Increase safety and patient care in relation to the use of medicines, by creating systems that allow 
a better and faster detection of adverse reactions; 
 Improve and foster the national systems in detecting problems related to the use of medicines and 
communicate those findings within the proposed calendars; 
 Contribute to a better understanding of the adverse reactions mechanisms and thus develop 
strategies to prevent those from occurring;  
 Prevention of harm and maximization of benefit; 
 Stimulate the rational and correct use of medicines; 
 Promote training in understanding and management of pharmacovigilance information. 
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1.1 Historic perspective – Pharmacovigilance  
 
It is known since the antiquity that a drug has its risks, and therefore the benefits must overweight these 
adverse effects or at least they must be acceptable taking into account the severity of the disease.  Safety 
and doing no harm are concepts that have been around since Hammurabi code (2200 a.C.) and then later in 
the Hippocrates oath (460-370 a. C.) (4). However took many years and some well-known disasters, which 
the most well-known is the thalidomide disaster, to officially create the pharmacovigilance. 
With the socioeconomic and scientific “explosion” in the final part of the XIX century, the medicines and the 
food products were produced in an industrial and unsanitary manner, which collided with the publication of 
a several articles by Upton Beall Sinclair Jr. describing the poor and negligent production of meat in the 
Chicago butchers (4). This was probably one of the reasons for the creation and publication in the United 
States of America of the “Pure Food and Drug Act” legislation in 1906, that prohibited the fake 
advertisement and the obligation to reveal the content of the products, through labeling of contents and 
dosage of each one (4).  
Later in the XX century, in 1938, the “Federal Food, Drug and Cosmetic Act” legislation was published and it 
stated that every manufacturer has to prove that its drugs are safe for human use before entering into the 
market, which resulted with the obligation to conduct pre-clinical toxicity studies. This law was approved 
due to a 105 dead from renal impairment as result of the use of elixir sulfanilamide (5). In the early 50s, the 
Durham-Humphrey Amendments were created in the United States and it determines that certain 
medicines should be sold only with a medical prescription (4).  
Later in 1960s, the Kefauver-Harris Amendments were published, and it specified that before using a 
medicine in humans it has to undergo a series of pharmacological and toxicological studies to prove its 
safety and efficacy. This legislation was created due to the thalidomide disaster. This medicinal product 
became very popular as sedative for morning sickness in pregnant. However, in April 1961, obstetrician 
William McBride notice that the cases of a rare birth called phocomelia in babies whose mothers had used 
thalidomide in pregnancy. He required the interruption of the using of this drug at the Crown St. Women’s 
Hospital, where he practiced and he also wrote of his concerns to Distillers, the company that sold the drug 
in Australia. He wrote another letter to a leading medical journal, The Lancet describing the relation 
between phocomelia and the consumption of thalidomide during pregnancy. The concern of McBride about 
this drug saved countless babies form being born with bird defects.  (6) 
Therefore, due to the thalidomide disaster in 1961 the first systematic international efforts were initiated to 
address drug safety issues (3). The non-existence of organized safety monitoring systems was the main 
cause of the 4 year interval between its entering into the market and the detection of the teratogenic effect 
of this drug, which result in hundreds of cases of phocomelia, which would have been avoided if an 
effective national and international monitoring system was implemented at the time of this disaster (7). 
Therefore the main lesson from thalidomide is that active systems for detecting hazards are needed and 
that the safety monitoring of a medicine should start long before it is on the market. 
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Later in 1963, the World Health Organization (WHO) organized a forum for discussion termed the Sixteenth 
World Health Assembly were the resolution (WHA 16.36) was adopted. This resolution reaffirmed the need 
for early action in regard to rapid dissemination of information on adverse drug reactions, and therefore it 
led, in 1968, to the  development of an international project to construct a system for the detection of ADR 
of medicinal products, it was called: “International Program of Adverse Reaction Monitoring”, which aimed 
to promote the fast dissemination of safety information, specially the information regarding adverse events 
(8) (3). This program was based on the previous experience of the 10 following countries: United Kingdom, 
United States of America, Federal Republic of Germany, Canada, Netherlands, Ireland, Sweden, New 
Zealand, Australia and Czechoslovakia (8). The World Health Organization centre was first established on 
1968 in Alexandria in the USA, however it was then moved to Uppsala in Sweden in 1978, called “Uppsala 
Monitoring Centre – UMC” (4). The principal aim of this program is to manage the international database of 
ADR reports received from National Centres (3) (9). In this Centre the spontaneous reports of all member 
states are collected, processed and stored.  
A WHO technical report on this program followed based on a consultation meeting held in 1971. (3) The 
principal achievement of the 1971 WHO consultation meeting was: 
 to advocate establishment of national centres for drug monitoring, 
 to provide guidelines, and 
 to identify the contribution that national centres might make to the international system. (3) 
In this meeting it was noted that involving the healthcare professionals, the systematic monitoring of 
populations, review of healthcare statistics and of drug utilization data and effective analysis of input data 
would be necessary for the achievement of pharmacovigilance objectives.  (3) 
Several systems were developed in WHO Member States in order to collect ADRs and evaluate them. The 
collection and analysis of these ADRs in a central database, would serve the important function of 
contributing to the work of national drug regulatory (3). The database controlled in UMC is called Vigibase 
and it is the WHO global individual case safety report (ICSR) database; it consists of reports of adverse 
reactions sent by each member of this program. National centres are requested to send to this database 
every ADR on a regular basis, at least quarterly; although the centres can report more frequently. (10) 
In order to facilitate the communication between countries and to promote the rapid safety signal 
identification, the Uppsala Monitoring Centre established standardized reporting rules to all National 
Centres (3).  
In the 1980s, the Council for International Organizations of Medical Sciences (CIOMS) in collaboration with 
WHO, launched a program on drug development and use. CIOMS provided a platform for recommendation 
from stakeholders (policy makers, pharmaceutical manufacturers, government officials and academics) on 
the communication of safety information between regulators and the pharmaceutical industry.  (3) 
The number of National Centres participating in the WHO International Drug Monitoring Program has 
increased. The role of these centres has contributed to the awareness of adverse drug reactions as a public 
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health concern; as a result, pharmacovigilance has become more than a regulatory activity, having a major 
role to play in clinical practice and the development of public health policy (3). To this fact contributes the 
location of the national and regional centres, which in the case of Portugal, the regional centres are located 
in universities and hospitals, which allows a closer relationship between the reporters and the National 
Authority (INFARMED, I.P.). In fact by April 2013 over 8 million reports were contained in the WHO 
database, making it the largest and most comprehensive pharmacovigilance database in the world (10).   
The growing number of Individual Case Safety Reports (ICSRs) sent to UMC since its creation till 2012 is 
presented figure 1 (11).  
 
 
Figure 1 – Growth of the ICSR in WHO database since 1967 till 2012. (11) 
 
According to WHO, the optimal Pharmacovigilance Centre (11):  
 sends ICSRs frequently (monthly, or at least once a quarter)  
 sends over 200 reports per million inhabitants per year   
 sends reports from different areas - geographical and medical  
 sends reports from vaccination and other public health programs  
 sends reports containing traditional medicines (herbals)  
 sends reports with as much information as possible  
 has performed a causality assessment of the reports. 
In order to regulate the activities related to medicinal product manufacturing, use and surveillance in 
Europe, the first European legislation regarding the use of medicines was the Directive 65/65/CEE of 26-01-
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65. This Directive was a reaction to the Thalidomide disaster; it aimed to harmonize standards for the 
approval of medicines within the European Economic Community (12).  
The Directive 75/318/EEC of 20-05-75, established the approximation of the laws of Member States relating 
to analytical, pharmaco-toxicological and clinical standards and protocols in respect of the testing of 
proprietary medicinal products (13). This directive wanted to bring the benefits of innovative 
pharmaceuticals to patients across Europe by introducing the mutual recognition procedure (13). The 
Directive states that Member States shall take all appropriate measures to ensure that the applications for 
marketing authorization are submitted by the applicants in accordance with the guidelines of the 
Directive(13). However it was the Directive 93/39/CEE of 14-06-93, amending Directives 65/65/EEC, 
75/318/EEC and 75/319/EEC in respect of medicinal products, that introduced major differences in terms of 
pharmacovigilance, which among other things, stated that each country should established its own 
pharmacovigilance system to capture the adverse reactions and to monitor all the medicines that are on the 
market, in addition, this directive also stated that the  person responsible for placing the medicinal product 
on the market shall be required to record and to report all suspected serious adverse reactions which are 
brought to his attention by a healthcare professional to the competent authorities immediately, and in any 
case, at the latest within 15 days of their receipt. Also in the scope of pharmacovigilance, this Directive 
specified that Member States shall take all appropriate measures to encourage physicians and other 
healthcare professionals to report suspected adverse reactions to the competent authorities and impose 
specific requirements on medical practitioners, in respect of the reporting of suspected serious or 
unexpected adverse reactions, in particular where such reporting is a condition of the authorization. 
Therefore, when as a result of the evaluation of adverse reaction reports, a Member State considers that a 
marketing authorization should be varied, suspended or withdrawn, it shall forthwith inform the Agency 
and the person responsible for placing the medicinal product on the market. Thus, in case of urgency, the 
Directive indicated that the Member State concerned may suspend a medicinal product marketing, 
provided the Agency is informed at the latest on the following working day. (14) (4) (12) (13) 
In Portugal, the first official rule was the Decree-Law nº 72/91 of 08-02-91- Estatuto do Medicamento. With 
the publication of this Decree-Law a new era in the national pharmaceutical sector begins, particularly in 
the field of marketing, quality control and manufacturing of medicines for human use. This document 
allowed to group every legislation on medicines of human use that were disperse, allowing the 
reorganization of this system in Portugal, with emphasis in quality assurance, safety and efficacy of 
medicines (15).  In terms of pharmacovigilance, this document stated that the marketing authorization 
holders (MAH), physicians, pharmacies’ technical directors and the other healthcare professionals, should 
communicate to Direcção Geral de Assuntos Farmacêuticos (DGAF) every adverse drug reactions that they 
become aware (15).  DGAF was the regulatory body responsible for the study of the safety information and 
for the proposition of measures considered appropriate to protect the public health. The DGAF was 
responsible, since its creation in 1984, for the monitoring of the pharmaceutical practice, licensing of 
manufacturers, wholesalers and pharmacies, and for the marketing authorization approvals for human and 
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veterinary use.  These were DGAF’s responsibilities till 1993, when the Decree-Law N.º 10/93 of 15-01-93 
determined the creation of INFARMED, I.P. (16) (17) 
However, a year before, the National Centre of Pharmacovigilance was created as a result of the regulatory 
dispatch N.º 107/92 of 08-02-92. This dispatch also established the creation of the national 
pharmacovigilance system. 
In the first years of the national pharmacovigilance system, healthcare professionals didn’t collaborate with 
the system as much as in other countries of Europe. However, the numbers of ADR reports grew with the 
Ordinance 605/99 of 05-08-99, where the objectives, functions and organization of the National System 
were clearly defined, this ordinance also stated that the system is under the responsibility of the INFARMED 
and that  pharmacovigilance regional units should be created, in order to decentralized the system and 
approach to the healthcare professionals and patients  (4). According to this Ordinance, the objectives and 
functions of the National Pharmacovigilance System were (18): 
 Collect, evaluate and disseminate information on the adverse drug reactions; 
 Identify as early as possible reactions that may occur with the use of medicinal product; 
 Examine and analyse, by processing the information and data collected, the possible existence of a 
causal relationship between certain medicinal product and an adverse reaction; 
 Establish the most appropriate methods for obtaining data on adverse reactions; 
 Systematically assess the safety profile of marketed medicinal products through the analysis of the 
relationship between risk and benefit of these medicinal products; 
 Develop technical standards for the use of medicinal products and trigger action to reduce their 
risks; 
 Collect data on consumption, as well as the misuse or abuse of drugs. 
The growing numbers in ADR reports were due to the publication of the Pharmacovigilance bulletin and the 
healthcare professionals’ education in pharmacovigilance. In fact the results several studies developed in 
the north region of Portugal, with the aim to analyse the effect of educational interventions in 
pharmacovigilance, showed that for both pharmacists (19) (20) (21) and physicians (22) (23) (24), face to 
face and regular education and qualification in pharmacovigilance is the key for higher rates for ADR 
reporting.  
Although some authors defend that spontaneous reporting systems are not enough robust to promote 
safety detection, since many adverse reactions are missed due to lack of interest, willingness, availability, or 
awareness of stakeholders to report (25). This generates a lower number of reports collected, which does 
not represent the experience of patients compared to systematic collection (26). I 
Therefore, information about ADR is limited and it does not represent the reality of adverse events resulting 
from drug use (19). The systematic collection of adverse drug reactions from patients may allow a better 
comprehension of the medicinal products safety profile, also providing a known dominator and a more 
comprehensive picture within a population.  A program with the aim of actively sought for adverse 
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reactions was described in a paper by Leone et al (27). The program was implemented in pharmacies, where 
information was systematically elicited from patients who were engaged by their local pharmacists. (27)  
Although in the future, the programs of systemic collection of ADRs may be implemented to a larger scale in 
Portugal, the establishment of educational programs, even during university, may help improve the number 
of notifications. In fact this number has been growing in the last decade, and ultimately, it has already 
reached the number recommended by WHO of 200 reports/million inhabitants. The values reflected in 
figure 2, reveal that Portugal has become a very active country in the matter of pharmacovigilance. (28) 
 
 
Figure 2 - Number of ADR reports received by source. This graphic represents the evolution of the number 
of ADR reports since 1992 till 2012 in Portugal, sent by the pharmaceutical industry, consumers and 
healthcare professionals. (Subtitles: yellow marker: physicians; blue marker: pharmacists; green marker: 
nurses; orange marker: pharmaceutical industry; grey marker: consumers) 
 
Over the years international legislation regarding pharmacovigilance changed in various ways. The Directive 
2001/83/EC of the European Parliament and of the Council of 06-11-01 was created to describe the 
essential aim of any rules governing the production, distribution and use of medicinal products. This 
Directive concerns all medicinal products, although for pharmacovigilance it is most relevant to products 
authorised by the national, mutual recognition and decentralised procedures. The Member States are the 
licensing authorities in these procedures. In terms of pharmacovigilance, this Directive stated that the 
member states should maintain a national system for the collection of safety information of medicinal 
products, namely ADRs. This system should aim the evaluation of this information, in order to avoid or 
minimize the risks associated with medicinal products. The MAH should apply a system for risk 
management for each medicinal product; monitoring the results of risk minimization measures and 
maintaining the risk management system updated. This directive also foresees that a Marketing 
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authorization may be withdrawn, suspended, revoked due to the safety evaluation of pharmacovigilance 
data. It also describes the situations in which a member state initiates a process termed Urgent Union 
Procedure. These were only a few measures implemented with this Directive within the European Union. 
(29) 
The Regulation N.º 726/2004 concerns centrally authorized products. The European Commission is the 
licensing authority for these products. In terms of pharmacovigilance, this Regulation increases the market 
safety surveillance by reinforcing monitoring procedures. It also stated that marketing authorization 
applications issued prior to 2 July 2012 were not obliged to implement a risk management system for each 
medicinal product. However, the Agency may nevertheless impose upon the holder of a marketing 
authorisation an obligation to implement such a system if it detects risks that might modify the risk-benefit 
balance of an authorised medicinal product. (30) 
Over the past few years, both Directive Nº 2001/83/EC and Regulation Nº 726/2004 had several amending 
acts, in which the last ones were the new Directive Nº 2010/84/EC amending, as regards pharmacovigilance 
Directive 2001/83/EC on the Community code relating to  medicinal products for human use and the 
Regulation Nº 1235/2010 amending, as regards pharmacovigilance of medicinal products for human use the 
Regulation (EC) No 726/2004 laying down Community procedures for the authorization and supervision of 
medicinal products for human and veterinary use and providing the legal basis for the European Medicines 
Agency, and Regulation (EC) No 1394/2007 on advanced therapy medicinal products. (31) (32) 
In Portugal, the Decree-Law N.º 242/2002 of 05-11-02 was created to apply Directive 2001/83/EC of 06-11-
01 to national law in terms of pharmacovigilance, it established the scope objective and organization of the 
national pharmacovigilance system. It also recognized the important roles of the healthcare professionals 
and the pharmaceutical industry in this system. (33) 
Later in 2006, the Decree-Law N.º 176/2006 of 30-08-06 was approved, which unifies all applicable 
pharmaceutical legislation, including all pharmacovigilance aspects. (34) This regulatory paper, establishes 
the legal regime for marketing authorization and its amendments, the manufacture of medicinal products, 
import, marketing, labelling and information, advertising, pharmacovigilance, and use of medicinal products 
and their inspection. (34) 
The Decree-Law N.º 20/2013 of 14-02-03 is the seventh amendment of the Decree-Law N.º 176/2006. The 
Decree-Law N.º 20/2013 aims to translate into national legislation the Directive 2010/84/EC, previously 
discussed.  This Decree-Law introduced, in terms of pharmacovigilance, several changes that aim a to 
reformulate the National Pharmacovigilance System with the goal of a better detection, motorization and 
supervision of risks associated with the use of medicinal products (35). 
Pharmacovigilance is now a dynamic clinical and scientific discipline, and it needs to develop further to 
meet public expectations and the demands of modern public health. (36) 
Although Pharmacovigilance is a confidently established science, it faces some major challenges, such as the 
globalization, which allows populations to access to medicines at a larger scale.  The wider access to the 
internet facilitates the dissemination of safety information that may not be accurate and it allows the selling 
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of medicinal products across national borders and even falsified medicinal products, which consists in one 
of the biggest risks for human health. The broader safety concerns are another major challenge of 
pharmacovigilance because there is a realization that adverse drug reaction may occur outside the terms of 
marketing authorization instead of within a specific dose range (the new definition of pharmacovigilance 
foresees the use within and outside the terms of marketing authorization). However these concerns and the 
acknowledgment of the harm caused by adverse reactions and the morbidity and mortality due these 
adverse reactions are finally being recognized as an important item on the European Community agenda. 
(36) 
Pharmacovigilance has a crucial role in meeting the challenges posed by medicinal products. Therefore, it is 
essential that when adverse effects and toxicity do appear, especially when previously unknown, these are 
reported analysed and their importance and significance is effectively communicated to the consumers and 
healthcare professionals. The harm associated with a medicinal product can be minimized by ensuring that 
medicines of good quality, safety and efficacy are used rationally, and that the expectations and concerns of 
the patient are taken into account when therapeutic decisions are made. To accomplish this, there is a need 
to ensure that the risks are anticipated and managed, and this is achieved through the empowerment of 
consumers, making them a central piece in the system and to provide regulators with the necessary 
information to amend and improve the legislation and recommendations on the manufacture and use of 
medicinal products, improve communication between the health professionals and the public and educate 
health professionals to understand the effectiveness or risk of medicines that they prescribe. (36) 
Therefore the description and analyses of the latest regulatory framework for pharmacovigilance is 
discussed ahead in this document.   
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1.2 State of the Art  
 
Currently an ADR is one of the leading dead causes in many countries. It is estimated that 197,000 deaths 
per year in the EU are caused by ADRs and that the total cost to society of ADRs in the EU is €79 billion (37). 
The Volume 9A was the main guideline for governing Medicinal Products in the EU (38); it contained the 
guidelines on pharmacovigilance for medicines for human use and it is divided in four parts. The first 
concerns the guidelines for marketing authorisation holders, the second, guidelines for competent 
authorities and the Agency, the third, guidelines for marketing holders, competent authorities and the 
Agency on electronic exchange of pharmacovigilance information in the EU, and the final part contains the 
guidelines for marketing authorisation holders and competent authorities on pharmacovigilance 
communication.   
The new European Pharmacovigilance Legislation applies to all medicinal products authorised in the EU, 
independently the procedure used for their approval. The European Union legal framework for medicinal 
products for human use is given in Regulation (EC) No 726/2004 and Directive 2001/83/EC. However in 
terms of pharmacovigilance and as previously described, in December 2010, a new Pharmacovigilance 
legislation (Regulation (EU) No 1235/2010 and Directive 2010/84/EU) was adopted by the European 
Parliament and European Council, however they only came into force in July 2012.  
The new legislation was created to make roles and responsibilities more clear, strength the EU network and 
ensure robust and rapid EU decision-making, to minimise duplication of effort,  to increase the levels of 
transparency of procedures, to promote higher quality of safety data,  and to make a proactive, science 
based and proportionate risk management. (39)  It also promotes a greater involvement of consumers in 
the pharmacovigilance system, by engaging them in decision making and in the reporting of adverse 
reactions directly to INFARMED. (7) To achieve these objectives, several initiatives are being implemented 
with the new legislation, for instance, the network between EMA (European Medicines Agency), Member 
States, Pharmaceutical Industry, healthcare professionals and consumers is more clear and the involvement 
of each one of these stakeholders in the promotion of public health is reinforced. The role of the EMA in 
improving coordination between Member States is strengthened through the creation of new committee, 
the Pharmacovigilance Risk Assessment Committee (PRAC) (40). It was also clear that the responsibilities of 
MAHs for pharmacovigilance should be clarified. These responsibilities are described in the Directive 
2010/84/EC, which states that MAHs should be responsible for continuously monitoring the safety of its 
medicinal products, for informing the authorities of any changes that might impact on the marketing 
authorization, ensuring that the product information is kept up to date, providing all available information, 
including the results of clinical trials or other studies, as well as reporting any use of the medicinal product 
which is outside the terms of the marketing authorization. (31) On the other hand Competent Authorities 
are empowered to enforce the collection of safety and efficacy information through post-authorization 
safety studies as a mandatory requirement to grant marketing authorization.   
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In order to minimize the duplication of effort, the coordination group should agree on a single position for 
pharmacovigilance assessments concerning medicinal products authorised in more than one Member State 
and in the case of products centrally authorized the European Commission is the regulatory body to decide 
and adopt harmonised measures. (31) 
The new timelines for decision making for marketing authorized medicinal products, faster warnings, 
restrictions and improvements to product information, allow a stronger link between safety assessments 
and regulatory action.    
To promote the high quality of safety data, the Commission in collaboration with the Agency, Competent 
Authorities and other stakeholders, should present an assessment report regarding the readability of the 
summaries of product characteristics and the package and propose, if necessary, changes and 
improvements in these texts.  (31)  
The definition of ADR was changed to become more comprehensive, it includes, besides the use within the 
marketing authorisation, the uses outside the marketing authorisation, since a considerable amount of 
adverse reactions occur when the medicinal product is used outside the terms of marketing authorization, 
the medication errors, overdose, abuse, misuse and occupational exposure (41).The new legislation 
determines that an ADR is a  response to a medicinal product which is noxious and unintended (31). With 
the new legislation the MAH has to submit all ADR directly and only to EudraVigilance, however this will 
only be possible in 2015, when this database is fully ready to receive all notifications (41). These reports will 
be immediately forward to the Member State on the adverse reaction occurred. With this patients will also 
be able to notify without previous medical conformation. (41) These type of system where the consumers 
report directly to competent authorities all suspected adverse reactions were already operating in some EU 
Member States, notably the UK, Denmark and Netherlands, where their impact is positive (40). 
There will be changes in the content and submission of periodic update safety reports and risk management 
plans to make them more rigorous, science-based approach that integrates the concepts of benefit-risk 
balance and risk-minimization measures, in order to make a proactive and proportionate risk management. 
To facilitate a single evaluation of PSURS with the same active substance or combination of active 
substances, the dates and frequency for submission of PSURs are harmonized, which avoids the duplication 
of effort and resources. (31) 
With the submission of all ADRs directly to Eudravigilance, the scope of periodic update safety reports has 
changed to a benefit-risk analysis rather than just listing of individual cases. (31) The pharmacovigilance 
measures for risk management planned by each marketing authorization holder for each individual 
medicinal product, should be proportionate to the identified risks, the potential risks, and the need for 
additional information on the medicinal product. (31)  
It is also one of the major goals of the new legislation to promote the transparency and openness, therefore 
each Member States will be obliged to set up and maintain national medicines web-portals with (40): 
 Summaries of product characteristics 
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 Package leaflets  
 Summaries of the risk management plans for authorized medicinal products  
 The list of medicinal products that are subject to additional monitoring 
 Information on the different ways of reporting suspected adverse reactions to the national 
competent authorities by healthcare professionals and patients 
The national web-portals will be linked to a European medicines portal. This will include(40): 
 information about the EMA Pharmacovigilance Risk Assessment Committee and its meetings;  
 post-authorization study’s conclusions;  
 summaries of risk management plans;  
 list of locations of the pharmacovigilance master files;  
 information about Union reference dates and frequency of submission of periodic safety update 
reports;  
 protocols and public abstracts of results of the post-authorization safety studies;  
 information on the initiation of urgent union procedures (including the active substances or 
medicinal products concerned, the issue being addressed, any public hearings and information on 
how to submit information and participate in public hearings;  
 the conclusions of assessments, recommendations, opinions, approvals and decisions taken by the 
PRAC and Committee for Medicinal Products for Human Use (CHMP) and by the Coordination 
Group, the national competent authorities and the Commission in the framework of assessment of 
periodic safety update reports.  
Each medicinal product under additional monitoring will be identified by a black symbol and a standardized 
explanatory sentence in the summary of the product characteristics and in the package leaflet: “
This medicinal product is subject to additional monitoring.” These medicinal products are available in a 
European list of medicines under additional monitoring is available. A medicine remains under additional 
monitoring for five years or until the PRAC decides to remove it from the list. However a medicine can be 
included on this list when it is approved for the first time or at any time during its life cycle. (42)  (31)  
Some features of the new legislation will only be applicable over the coming years; therefore European 
Commission published the transitional arrangements concerning the entering into force of the new rules of 
pharmacovigilance.      
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2. Training Objectives 
 
The objectives for my training are:  
 To know how a regulatory authority for medicines works and how it articulates with the European 
Medicines Agency;  
 To apply the multi-disciplinary background and the knowledge that was acquired during the 
biomedical sciences course and the master’s degree course to the practice of a pharmacovigilance 
department at a regulatory authority;  
 To acquire experience in medicines monitoring and risk management; 
 To gain a deep knowledge about the pharmacovigilance legislation and procedures; 
 To be actively involved in the directorate daily activities;  
 To aim my personal and professional development; 
 To contribute to the improvement of public health. 
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3. Vision about the host institution – INFARMED 
 
INFARMED was created in 1993 with the promulgation of Decree-Law N.º 10/93 (16).  It is the national 
authority responsible for the regulation of the sector of medicines, medical devices, cosmetic and body 
hygiene products, according to the high standards of public health protection. It assures the access to 
quality, effective and safe medicines, medical devices, cosmetic and body hygiene products by healthcare 
professionals and patients (43). 
 
The main mission and duties of INFARMED are (44): 
a) Contribute to the creation and development of the health policy, including the definition and 
implementation of policies for human medicines, medical devices, cosmetics and products for 
personal hygiene; 
b) Ensure the regulation and supervision of research, production, distribution, marketing and use of 
human medicines, medical devices, cosmetics and products for personal hygiene, according to 
their jurisdictions; 
c) Ensure compliance with the standards for authorization of clinical trials with human medicines, as 
well monitoring compliance with good clinical practice; 
d) Ensure quality, safety, efficacy and cost-effectiveness of medicines for human use, medical devices 
and cosmetics and personal hygiene products; 
e) Monitor the consumption and use of medicines and medical devices for human use; 
f) Promote the access for healthcare professionals and consumers to information necessary for the 
rational use of medicines for human use, medical devices, cosmetics and products for personal 
hygiene; 
g) Promote and support, in conjugation with universities and other research and development units, 
national or foreign, the study and investigation in the domains of science and pharmaceutical 
technology, biotechnology, pharmacology, pharmacoeconomy and pharmacoepidemiology;  
h) Ensure proper integration and participation within the European Union system for the evaluation 
and supervision of medicinal products for human use, including coordination with the European 
Medicines Agency and the European Commission and other European Institutions; 
i) Ensure the proper integration and participation within the network of national authorities 
responsible for medicines, medical devices and cosmetics and personal hygiene products of the 
European Union and within the network of official laboratories for medicines’ validation of quality 
in Europe;  
j) Ensure other international obligations of the State within its powers, particularly within the 
European Union, as well within the European Council and especially the European Pharmacopoeia 
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Commission and the United Nations in the area control of narcotic drugs and psychotropic 
substances;  
k) Develop activities of national and international, bilateral or multilateral nature, within the scope of 
its responsibilities.  
 
 
The activities performed by INFARMED, I.P. are presented in the next figure, it illustrates the life cycle of 
medicines and health products. 
 
 
Figure 3 –Respresentation of the life cicle of a medicinal product,  from its investigation till its use by the 
consumers. In this diagram the pharmacovigilance assumes a central role, since it is present in every phases 
of this cycle (45). (Subtitles: the first step of this life cycle is investigation and development followed by 
clinical trials; authorization, manufacturing, wholesale distribution, prescription, dispensation and 
utilization of a medicine. The fisrt grey marker is the technical and scientific evaluation and the second one 
is the reimbursement and economic evaluation).   
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3.1 Direção de Gestão do Risco de Medicamentos 
 
Direção de Gestão do Risco de Medicamentos (DGRM) is the directorate within INFARMED, responsible for 
the monitoring of the medicines with a marketing authorization in Portugal. It has the responsibility (46) of: 
 Ensure the coordination and functioning of the National Pharmacovigilance System of Medicines 
for Human Use, particularly for the collection, evaluation and dissemination of information on 
suspected adverse drug reactions, for the analysis of causal relationship between medicinal 
products and adverse reactions and the early identification of safety problems with the use of 
medicines; 
 Manage the European  pharmacovigilance alerts system within the European Union and ensure the 
participation in the Program for International Drug Monitoring of WHO; 
 Ensure the safety monitoring of medicines through the evaluation of risk management plans; 
 Promote and conduct epidemiological studies, propose and implement safety measures and 
reports on benefit-risk; 
 Coordinate the activities of pharmacovigilance units that integrate the National Pharmacovigilance 
System; 
 Collaborate with other national and international entities in the promotion and performance  of 
studies in the field of medicines epidemiology;  
 Ensure the dissemination of safety information to health professionals and the general public;  
 Ensure liaison with the Evaluation of Medicines Commission regarding pharmacovigilance, except 
in what regards Periodic Safety Update Reports; 
 Collaborate in the activities of regulatory and scientific advice; 
 Ensure coordination with national and European information systems within its competence; 
 Ensure, within its mission, the representation of INFARMED, I. P., at a national and international 
level, including the EMA’s Pharmacovigilance group and pharmacovigilance centers of other 
National Medicines Agencies.  
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Figure 4 - INFARMED’s organizational chart. (47)
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3.2 INFARMED, I.P. Quality System  
 
Quality is a responsibility share by all the Infarmed’s Collaborators. To assure that procedures are 
implemented and executed in with the highest standards, a set of values were defined and implemented 
that are a guide in the process of decision making.  
 
The Infarmed’s Quality Policy is based on the following 4 principles (48): 
 
 
 
The processes are divided in 3 classes:  
 
Planning and management processes: processes related with the planning and monitoring of Infarmed’s 
activity and system continuous improvement; 
Business processes: processes related with the completion of a service; 
Support process: processes that aid the business processes.  
 
DGRM Quality System  
 
DGRM is one of the certified directorates in INFARMED. The certification is based on the NP EN ISO 
9001:2008 – Requirements for Quality Systems. The quality system is based on the construction and 
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improvement of Standard Operating Procedures (SOPs), each one of these SOPs is developed by DGRM 
collaborators for each procedure. 
 
The process designation for DGRM activities is Safety Monitoring and it described as the monitoring of 
safety of medicines for human use through the management and evaluation of the adverse reaction 
reporting, of the periodic safety update reports and other data with the purpose of detect and evaluate 
signals and communicate safety information.  
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4. Regulatory entities and groups that coordinate Pharmacovigilance 
 
Besides the INFARMED, I.P. and more precisely DGRM, there are other important regulatory entities that 
act at an international level for coordination of Pharmacovigilance.  
 
European Medicines Agency 
 
The EMA is a decentralized agency of the European Union and it has the responsibility to protect and 
promote the public and animal health, through the evaluation and supervision of medicines for human and 
veterinary use (49). It is responsible for the pharmacovigilance of human and veterinary medicines, with 
strict collaboration with the European National Competent Authorities, such as INFARMED, in terms of 
evaluation of the quality, safety and efficacy of medicinal products that falls within the European legislation 
(49) 
It provides the necessary input for efficient and transparent evaluation procedures to help bring new 
medicines to the market, through a centralized procedure for certain medicines. With this procedure the 
companies submit a single marketing authorization application to the Agency. (49)  
The Agency also develops new strategies to promote the research and development of new medicines for 
public health needs and provides scientific advice and incentives to stimulate the development and 
promote the availability of new innovative medicines and ensure their benefits overweigh their risks. (49)  
In terms of pharmacovigilance the Agency monitors the safety of medicines through a pharmacovigilance 
network, and it may take any appropriate action to protect public health, if any safety signal arises and it is 
suggested that the benefit-risk balance of a medicine has changed since it was authorized. (49) It also 
establishes guidelines and gives the most input for development of new legislation. 
 
EMA - EudraVigilance database 
 
EudraVigilance (EV) is a database that contains adverse reactions reports received from all the 
regulatory agencies within European Union and from pharmaceutical companies. It currently 
contains adverse reactions reports on authorized and licensed medicines from across Europe. This 
information is shared by national competent authorities (40) (50). It also allows the processing, 
management and evaluation of suspected adverse reactions. (51) (50) 
It is one of the most important tools in pharmacovigilance, because it allows the evaluation of 
safety signals at a bigger scale, since it collects all the ADR from EU.  
It is stated in the new legislation that since July 2012, the role of Eudravigilance is expanded: It has 
become the single point of receipt for all pharmacovigilance information for medicines for human 
use authorized in the EU. Companies and Member States will report reactions directly to 
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Eudravigilance, which will immediately notify all Member States electronically. However this 
database is not ready to receive all adverse reaction from the UE, therefore the direct sending of 
ADRs from MAH to EV will be fully implemented in 2015. (40) 
 
EudraVigilance supports the (50):  
 Electronic exchange of suspected adverse reaction reports (referred to as Individual Case 
Safety Reports) between the EMA, National Competent Authorities, MAH, and sponsors of 
clinical trials in the EEA;  
 Early detection of possible safety signals associated with medicinal products for Human 
Use;  
 Continuous monitoring and evaluation of potential safety issues in relation to reported 
adverse reactions; 
 Decision making process, based on a broader knowledge of the adverse reaction profile of 
medicinal products especially in the frame of Risk Management.  
 
Committee for Human Medicinal Products 
 
The CHMP is responsible for preparing the opinion of the Agency on any question relating to the evaluation 
of medicinal products for human use. It can also provide and request opinions to other committees and 
working parties. (52) 
In matters of pharmacovigilance, the committee responsible for the evaluation of the safety information is 
the PRAC. However it shall transmit any recommendation to CHMP for adoption.  Till July 2012, the 
Pharmacovigilance Working Party (PhVWP) was the entity responsible for the evaluation of safety 
information, however since this date it was replaced by PRAC. (52) 
 
Co-ordination Group for Mutual Recognition and Decentralized Procedures – Human 
 
The CMD(h) (Co-ordination Group for Mutual Recognition and Decentralized Procedures – Human) is a 
group established in 2004, to provide and examine any question related to marketing authorizations 
through mutual recognition or decentralized procedures (53). Its role is to consider cases of disagreement 
between Member States involved in a mutual recognition or decentralized procedure on the assessment 
report, the summary of product characteristics, the labeling or the package leaflet on the grounds of 
“potential serious risk to public health”. (40) 
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This group has as its priority to collaborate with PRAC to make recommendations and propose actions in 
relation to risk management strategies for products approved through mutual recognition and 
decentralized  procedures (53). 
Pharmacovigilance Risk Assessment Committee 
 
The PRAC  is the committee responsible for the evaluation of the safety information, and therefore it carries 
out most of the Agency’s work on pharmacovigilance (54). Several experts from each of the national 
authorities in Europe are part of it, as well specialists of each scientific area that give inputs and opinions in 
several issues (54).The PRAC will advise the Coordination Group and the CHMP on all aspects of the 
assessment of pharmacovigilance data after the authorization of a medicine (40). 
It assesses all aspects of risk management of medicines for human use, which includes detection, 
assessment and evaluation of all adverse reactions to medicinal products and subsequent risk 
communication. It is also responsible for the design and evaluation of pharmacovigilance audit and post-
authorization safety studies. (40)  
 
 
World Health Organization 
 
WHO has a major role in the pharmacovigilance at an international level. This organization is responsible for 
coordinating and directing the health system within its country members. It is also responsible for providing 
leadership for health questions and issues at a global level, and determining the world health agenda, 
setting norms and standards, providing technical support to countries and monitor and assess health 
trends. (55) 
WHO developed the Program for International Drug Monitoring, that aims is monitor the safety profile of a 
medicine at an international level. The operating centre of this initiative is at Uppsala Monitoring Centre 
(UMC). The main goal of this Centre is to protect public health and to improve patient safety and welfare by 
reducing the risk of medicines (8). Several centers work with UMC, by collecting all suspects of adverse 
reactions, and then sending them to UMC for entry into the WHO database. (10) The WHO’s database is the 
VigiBase and it is the global ICSR database; it consists of reports of adverse reactions received from the 
countries that are registered in this program. (10)  
 
International Conference on Harmonization of Technical Requirements for Registration of 
Pharmaceuticals for Human Use  
 
The ICH (International Conference on Harmonization of Technical Requirements for Registration of 
Pharmaceuticals for Human Use) is a joint initiative between Industry and Authorities as partners in 
discussion, to ensure safety, quality and efficacy of drugs.  ICH’s mission, as stated in its site, is “to make 
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recommendations towards achieving greater harmonisation in the interpretation and application of 
technical guidelines and requirements for pharmaceutical product registration, thereby reducing or 
obviating duplication of testing carried out during the research and development of new human medicines. “ 
The ICH was created after the demonstration, in 1980 by the European Commission, that harmonization in 
regulatory and scientific development of a new medicine, was possible and needed. Therefore plans for 
creating ICH were made at the WHO Conference of Drug Regulatory Authorities, in 1989. The official 
creation of this Conference took place at a meeting in Brussels in 1990. Attending to the meeting were 
representatives of regulatory authorities and industry associations of Europe, Japan and USA. (56) 
So far many guidelines have been created to ensure safety, effective and high quality medicines. These 
technical documents have been developed to prevent the duplication of work and efforts, promote public 
health, prevent unnecessary duplication of clinical trials in humans, and minimize the animal testing. (56) 
 
Council for International Organizations of Medical Sciences 
 
CIOMS (Council for International Organizations of Medical Sciences) is an international non-governmental 
organization established by the World Health Organization and by the United Nations Educational, Scientific 
and Cultural Organization (UNESCO). It represents de biomedical scientific community (57)  
The objectives of this organization are (57):  
 Facilitate and promote international activities in the field of the biomedical sciences.  
 Collaboration with the United Nations and its agencies 
 Serve the international interest of international biomedical community.  
It has several work groups, which are responsible for the analysis of several topics in pharmacovigilance. 
The more important working groups are CIOMS I (reporting adverse drug reactions); CIOMS II (Preparation 
of periodic safety update reports); CIOMS III (Rules for Company Core Safety Information); CIOMS IV 
(benefit-risk assessments); CIOMS V (practical issues in pharmacovigilance); CIOMS VI (clinical trial safety 
data); CIOMS VII (development safety update reports); CIOMS VIII (Practical Aspects of Signal Detection in 
Pharmacovigilance); CIOMS IX (Practical Considerations for Development and Application of a Toolkit for 
Medicinal Product Risk Management); CIOMS X (Considerations for applying good meta-analysis practices 
to clinical data within the biopharmaceutical regulatory process). (57) 
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5. National Pharmacovigilance System  
 
As already described, the national system of pharmacovigilance was created in 1992 (4). It was established 
by the Decree-law N.º 72/91, which states that the MAH, physicians, pharmacies technical directors and 
other healthcare professionals should communicate to INFARMED, all ADR that occurred due to the intake 
of a medicinal product. In the years following the publication of this Decree-Law,  an effort to improve the 
system was made, by introducing more human and material resources and through the dissemination of 
the system and notification forms to healthcare professionals and through the participation in international 
pharmacovigilance groups, such as PhVWP. (4) 
Later, the system was decentralized, to combat the under-notification of ADR; four regional units were 
created. Also with the aim to expand and develop the system, Portugal was involved in the development of 
adverse drug reactions database, being the first Member State to use the then new electronic transmission 
system of pharmacovigilance data (Eudravigilance). (4) (18) 
The main source of information in the national pharmacovigilance system is based on the spontaneous 
reporting of cases of adverse reactions by the healthcare professionals, MAH and consumers. (7)However 
the sources of the pharmacovigilance information are diverse, therefore it also includes clinical and 
epidemiological studies, literature, data bases, additional monitoring of medicines, surveillance programs, 
etc (4). Both serious and non-serious reactions should be reported, since is this type of information that 
may change the benefit risk balance of a medicine and it also contributes for a deeper knowledge of a 
medicines safety profile. These notifications may be sent to the Regional Units or directly to DGRM, they 
can also be sent to marketing authorization holders, which in this case these notification should be sent to 
INFARMED for safety analysis (4). After the reception and treatment of each notification, a causality 
assessment is performed.  
 
 
Figure 5 - Structure of the National Pharmacovigilance System. (58) 
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The national pharmacovigilance system is responsible for (35): 
 Systematic collection of all information related with the risk of medicines for patients and public 
health, especially in what regards to adverse reactions: 
o In the human being, derived from the use of medicines in the terms of MA or outside of 
these terms, including overdose, misuse, abuse and medications errors; 
o Associated with occupational exposure; 
 Evaluation of the safety information collected and the safety profile of medicines; 
 Consideration of adequate safety measures for prevention or minimization of risks; 
 Handling and processing of safety information and its communication to the other Member States; 
 Adoption of the necessary regulatory measures; 
 Systematic assessment of the safety profile of marketed drugs, notably by examining the 
relationship between risk and benefit of medicines and other relevant issues, to analyze the need 
to adopt safety measures; 
 Participation in the preparation of technical and scientific standards for the correct use of 
medicines; 
 Implementation of safety measures to minimize the risks associated with the use of a medicine; 
 Communication and dissemination to healthcare professionals and general public, of any 
important information.  
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6. Developed Activities 
 
The activities developed in DGRM are divided in two main areas: risk management and monitoring.  
 
Figure 6 - Scheme that represents the activities developed at DGRM 
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6.1 Gant Chart  
 
 
 
This Gant Chart represents the activities developed during my internship and the duration of each one. It is divided in 2 major groups: the first represents the risk 
minimization activities developed during the internship and the second one the safety monitoring of medicines. This last group of activities is also represented in the 
internship extension, since those were the activities developed on this period of time.  
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6.2 Risk Management System 
 
The need for a risk management system arises from the fact that at the time of approval the safety 
information of a new medicine is relatively restricted. This is due to the fact that clinical trials are very small 
in terms of length and the amount of subjects and populations studied is very limited, which will lead to the 
non-detection of certain types of adverse reactions. 
The main objective of this system is to ensure that the benefits of a medicine overall the risks and therefore 
the risk minimization activities are performed to increase the benefits or reduce the risks of medicinal 
product. In order to perform this, each MAH should have a risk management plan for each one of his 
products. (59) 
In the context of risk management, competent authorities have to ensure that constant monitoring is being 
done and that any relevant information on medicines is transmitted to patients and healthcare 
professionals; ensure that any risk minimization activity is implemented and that these activities are being 
monitored for effectiveness; take appropriate regulatory actions to minimize the risks of the medicinal 
product and maximize its benefits (59) 
The topic on risk management systems is discussed in the Good Pharmacovigilance Practices – Module V 
(Risk management systems), and main difference between the GVP module and Volume 9A is the new 
approach to the risks through the understanding of risk in the context of benefit (38). To achieve this, the 
content of risk management plan has been changed and was added new sections to analyze the overall 
benefit of a medicine.  
  
Figure 7 - Risk Management Cycle (59)  
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6.2.1 Risk management Plan  
 
Risk Management Plan (RMP) serves as a basis for post-authorization pharmacovigilance activities.  With 
the new legislation, the content of a risk management plan has changed and now it also aims to analyze the 
effectiveness of the minimization activities. The main goals of RMP are (59):  
 Identify and indicate how to further characterize the safety profile of medicinal products;  
 Quantify and describe what is known and not known about the medicinal product;  
 Document minimizations measures adopted to prevent or reduce the risks associated with the 
medicinal product and how their effectiveness will be evaluated; 
 Document post-authorization obligations that have been imposed as a condition of marketing 
authorization; 
 Document the need for studies on efficacy in post-authorization phase.  
 
Before the new pharmacovigilance legislation came into force, a risk management plan had to be submitted 
in the form of an EU-RMP. An EU-RMP was not always needed to be submitted, although it may had to be 
submitted at any time of a product’s life-cycle (38).   
There are a few situations where a EU-RMP needed to be submitted (38): 
 At the time of marketing authorization: 
o Any product containing a new active substance;  
o A similar biological medicinal product;  
o A generic/hybrid medicinal product where a safety concern requiring additional risk 
minimization activities has been identified;  
 Request for a pediatric marketing authorization (PUMA); 
 Any application that involves great changes in the marketing authorization (e.g. new dosage form, 
new route of administration, new manufacturing process of a biotechnologically-derived product, 
significant change in indication, including a new pediatric indication) if it is stated as needed by the 
competent authority; 
 On the request from a Competent Authority (both pre-and post-authorization);  
 On the initiative of an Applicant/Marketing Authorization Holder when they identify a safety 
concern with a medicinal product at any stage of its life cycle.  
For some active substances that are seeking authorization via centralized procedure may be requested to 
submit a RMP, such as known active substances, hybrid medicinal products that suggest that additional 
activities are needed, bibliographical applications and fixed combination applications. (38) 
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With the new pharmacovigilance legislation the situations where a RMP is required are (59):  
 All new marketing authorization applications require the submission of a RMP; 
 Other situations where might be required the submission of a RMP are with an application 
involving a significant change to an existing marketing authorization (new dosage form; new route 
of administration; new manufacturing process of a biotechnologically-derived product;    pediatric 
indication); 
 Other significant change in indication, which can be a new disease area or a new age group; 
 It has also to be submitted at the request by the Agency or by a Competent Authority. It should be 
submitted when there is any significant change in the benefit-risk balance.  
 
The old EU-RMP contains two parts (38):  
 
Part I (38): 
 Safety Specification, 
 A Pharmacovigilance Plan. 
 
In this part, the safety profile of the medicinal product is analyzed according to the safety specification that 
has been identified. The safety specification is a summary of the important identified risks of a medicinal 
product, important potential risks, and important missing information.  (38) 
 Safety Specification  
 
The safety specification should include the non-clinical data, in this part the safety findings that have not 
been adequately addressed by clinical data. It should also contain the clinical information of the medicinal 
product, for instance the limitations of the human safety database, populations not studied in the clinical 
phase, the identified or potential risks that require further characterization or evaluation. (60) 
 Pharmacovigilance Plan  
 
The structure and length of the pharmacovigilance plan will depend on the product that is being under 
analysis. This plan has the main purpose of addressing the safety concerns identified.  (60) 
In the beginning of the Pharmacovigilance plan a brief summary about the important identified risks, 
important potential risks and important missing information should be provided. In this plan, the routine 
pharmacovigilance activities are described. It is also provided an overview about ADR reports preparation 
for  the competent authorities, such as expedited reports for adverse reactions and periodic safety reports; 
continuous monitoring of the safety profile of approved products and signal detection. (60) 
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However additional safety activities may be needed for medicines with important identified risks, important 
potential risks, or important missing information. These activities will differ according to safety specification 
identified. An example of one of these activities is a Pharmacoepidemiology study, to measure the 
incidence rate of ADRs in a different population (38). The studies that have the objective of measuring the 
effectiveness of risk minimization measures should be included in the pharmacovigilance plan and 
described with detail in the minimization plan. Examples of these studies are the drug utilization studies 
that measure the drug use in a specific country or by a specific population (38). 
In this plan, each safety concern should have an action plan that consists in the description of the safety 
concern, objective of proposed action(s), the action(s) that is/are proposed, rationale for proposed 
action(s), milestones for evaluating and reporting. (38) 
The plan should be organized according to the actions to be taken and their milestones and the actions to 
be completed. (38) 
 
Part II (38): 
 An evaluation of the need for risk minimization activities,  
 If there is a need for risk minimization plan 
 
 Evaluation of the need for risk minimization activities  
 
The evaluation of the need of risk minimization activities should be provided in RMP. Some safety concerns 
may be adequately addressed by the proposed actions in the Pharmacovigilance Plan, however for some 
other risks it may not be enough due to their seriousness, and therefore risk minimization activities are 
needed. (38) 
 Risk minimization Plan  
 
This plan describes the risk minimization activities proposed for a certain safety specification, to reduce the 
risks associated with an individual safety concern, and it may have one or more risk minimization activities. 
It should be developed on a case-by-case basis.  
The routine and the additional risk minimization activities should be described and the first ones are 
common for every medicinal product and those include (59): 
 The summary of product characteristics, package leaflet and labeling  
 The pack size(s) and validity  
 The legal status of the product  
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Impact of the new legislation in the Risk Management Plan  
 
With the new legislation the risk management plan has a new format and new section have been added to 
properly assess all the issues. The new format for the RMP is already mandatory, as stated in the 
Implementing Regulation (EU) No 520/2012, for all new MAA. It is divided in 7 parts and the part 2 is 
divided in 8 modules.  
As was with the old format, the risk management plan should be proportionate to the identified potential 
risks of the medicinal product, and the need for new post-authorization safety data.  
The information contained in these sections should include enough detail so that it can be understood and 
important information analyzed.  
New RMP format (59):  
 
Part I Product(s) overview  
Part II Safety specification  
Module SI Epidemiology of the indication(s) and target population(s)  
Module SII Non-clinical part of the safety specification  
Module SIII Clinical trial exposure  
Module SIV Populations not studied in clinical trials  
Module SV Post-authorization experience  
Module SVI Additional EU requirements for the safety specification  
Module SVII Identified and potential risks   
Module SVIII Summary of the safety concerns  
Part III Pharmacovigilance plan  
Part IV Plans for post-authorization efficacy studies  
Part V Risk minimization measures (including evaluation of the effectiveness of risk minimization 
measures) 
Part VI Summary of the risk management plan  
Part VII  Annexes 
 
At INFARMED, the RMP analysis was important to identify if a certain medicinal product is object of risk 
minimization measures and what type of pharmacovigilance activities are established for it. For instance, a 
well-known medicinal product that doesn’t have any special concerns in relation to its safety profile may 
only be targeted for routine pharmacovigilance activities, which are the set of activities required to fulfill 
the legal requirements for pharmacovigilance contained within Directive 2001/83/EC and Regulation (EC) 
No 726/2004. For example, a routine pharmacovigilance measure is the communication of safety 
information to patients and to healthcare professionals through the Patient Leaflet (PL) and the Summary of 
Product Characteristics (SmPC). However for some safety risks the routine measures may not be sufficient. 
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An additional pharmacovigilance risk management measure may be the creation of educational materials, 
which are evaluated for its pharmaceutical and medical precision and accuracy, at DRGM.  
Through the analysis of the RMP, it is possible to ensuring the implementation of risk minimization activities 
at a national level, and take appropriate regulatory actions to minimize the risks of the medicinal product 
and maximize the benefits.  
 
6.2.2 Risk Communication  
 
The risk communication is a part of the risk minimization activities; and as previously stated, it may be a 
routine activity for the information contained in the SmPC and the PL. However in certain cases, when there 
is a safety concern that cannot be managed though this type of safety communication, the important safety 
information may be distributed through Direct Healthcare Professional Communications or Information 
Circulars and additional educational materials should be distributed to the patients, patients’ families or to 
healthcare professionals. (38) 

 
6.2.2.1 Educational materials 
 
An educational program is one of many additional risk minimization activities and it may be based on 
several types of scientific documents to ensure that the medicine is safely used. (38) 
An educational material is a risk minimization activity, which is performed to reduce the risks associated 
with an individual safety concern. (38) 
The need for educational materials will depend upon the specific safety concern and it is specified at the 
time of marketing authorization. As stated in the volume 9A, the aims of these activities are (38): 
 Enhance understanding of the specific risk(s); 
 Enhance understanding of measures to reduce either the frequency or severity of adverse 
reactions; 
 Enhance early detection and treatment (if applicable) of an adverse reaction 
 Enhance patient information, awareness and provide information on the need and use of 
additional precautions.  
The type of educational materials will depend on the purpose and the target of these programs. It can be a 
physician's guide to prescribing, pharmacist's guide to dispensing; patient information brochures, checklists 
for both patients and healthcare professionals or specific training programs. (38) 
When a medicinal product is authorized, all information about the conditions/restrictions of MAA has to be 
analyzed at DGRM. This is performed to identify if an educational material is foreseen. If an educational 
material is expected, it has to be submitted to DGRM or requested to MAH by one of DRGM’s technicians. 
Upon receipt of this document, it is validated and analyzed by a DGRM technician. During the validation 
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certain aspects have to be considered, the coherence with the SmPC, the distribution universe (to whom 
will the material be distributed), data of dispatch and legal aspects.  
The INFARMED’s Advertising Team has a very important role in determining if the educational material has 
any content that may be transmitted as advertising to the target. 
After the educational material is analyzed and all information collected, it is sent to the MAH for review, 
and after all revisions, it is published at Infarmed’s website if allowed by the MAH.  
 
 
6.2.2.2 Direct Healthcare Professional Communication  
 
A Direct Healthcare Professional Communication is defined as the information about a specific medicine 
that aims to ensure its safe and effective use. It is delivered directly to individual Healthcare Professionals 
by a MAH or by a CA. It should be submitted to DGRM, for validation, even if its content has already been 
agreed by EMA or by other CA. (38) 
The information contained in these letters should be brought to the attention of Healthcare Professionals 
before to the general public. It may contain several types of information regarding suspension, withdrawal 
or revocation of a marketing authorisation with recall of the medicinal product from the market for safety 
reasons. It may also contain important changes to the SmPC, such as new contraindications, restrictions of 
indications, etc.). It is also used to inform that a referral procedure, which results in a significant change to 
the product information, was triggered for safety reasons. (38) 
When there is a need to transmit, to healthcare professionals, safety information about a medicinal 
product, the MAH should submit a DHPC to DGRM. The role of the DRGM’s technicians is to validate the 
letter, in terms of translation, content and to verify if the established requirements are fulfilled, such as 
information about the applicant and/or the MAH, the framework of the request, description of the DHPC 
distribution proposal (distribution universe – for whom; DHPC’s distribution method – email, mail, visit, 
etc.) and the agreed communication plan, or the date set for distribution. It may also be submitted by EMA, 
the reference member state or by the EC.   
The analysis of DHPCs aims to verify if it is consistent with the SmPC, and with the national applicable 
legislation. The message should be clear and concise, it should be objectively presented to the general 
public, it should also explain the reason for the distribution of the DHPC and it has to provide 
recommendations to healthcare professionals on how to minimize the risk.  
If in the process of analysis, there were any amendments to the DHPC, these should be discussed with 
DGRM’s Directorate, before sending it to the MAH, and only after the approval, it may be sent to the MAH. 
The final step of this process is to ask if the MAH authorizes the publication of the letter in INFARMED’s 
website.  
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6.2.3 Periodic safety update report 
 
A periodic safety update report is a pharmacovigilance document that is used to provide the benefit-risk 
balance of medicinal product information to the regulatory authorities, including the evaluation of this 
information. This document gives an update of the worldwide safety experience of a medicinal product 
(38). It is submitted at defined periods of time during the post-authorization phase. 
The need for PSURs arises from the necessity for a continuous risk and benefits evaluation of medicinal 
products that are already in the market and used in everyday healthcare practice. The marketing 
authorization holder should prepare a single PSUR for all its medicinal products containing the same active 
substance with information on all authorized indications, route of administration, dosage forms and dosing 
regiments, irrespective of whether authorized under different names and through separate procedures. 
(61) 
During my internship I had the chance to analyze and validate PSURs. I was responsible for the format 
evaluation and to verify if there was any safety concern described in the report. Before the new legislation, 
the marketing authorization holder had to submit its PSUR with the format established in the Volume 9A.  
The PSUR is received at DRGM, and then it is validated, to verify if it has a cover letter, a CD containing the 
report, the name of the MAH that is sending the PSUR and if the period covered by this report is 
mentioned. If all these elements are present and according with the established requirements, the report is 
archived or evaluated. It is evaluated by Portugal if it is the reference MS in case of a medicinal product 
approved through mutual recognition or decentralized procedure. In the case of a centralized product, it 
should be evaluated by the Rapporteur. After this evaluation, the preliminary assessment report is 
circulated for comments, and then the RMS or Rapporteur elaborates a final assessment report which is 
also disseminated for comments. This Assessment report will, if requested by the reference MS or by a 
concerned MS, be discussed at a PhVWP meeting. (38) 
After the evaluation of a PSUR, it may be determined that is necessary to take a regulatory action, which 
will be communicated to MAH after an agreement with CHMP. (38) 
Before July 2012, the legislation that stated the periodicity for submission of PSURs was Regulation (EC) No 
726/2004 and Directive 2001/83/EC. For products authorized after 02 July 2012 (centrally authorized 
products) and 21 July 2012 (nationally authorized products) the MAH shall submit at 6 months intervals 
once the product is authorized, even if it is not marketed; once the product is marketed, 6 monthly PSURs 
submission should be continued following initial placing on the market in the EU and until 2 years of 
marketing experience in the EU, then once a year for the following 2 years and thereafter at 3-yearly 
intervals. (61)  
The new format and content of PSURs are described in the guideline on good pharmacovigilance practices 
(GVP) – Module VII – Periodic Safety Update Report. There are some changes between what is described in 
this module and what is sated in Volume 9A relating to PSURs.  
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According to Volume 9A, each PSUR that arrived to DGRM, during my internship, should had the following 
structure (38): 
The title page should contain the product name, the MAHs name and address, period covered by the 
report, the international birth date, the report date and any other identifying information at the option of 
MAH. 
 Executive Summary: where the MAH should present a brief PSUR’s overview to provide the reader 
with a description of the most important information.  
 Introduction: where is introduced the product and place a perspective of previous reports. 
 World-wide market authorization status (information usually provided as a table):  
o Dates of marketing authorization and renewal; 
o Any qualifications surrounding the authorization;  
o Treatment indications and special populations covered by the marketing authorization; 
o Lack of approval, with an explanation by the regulatory authorities; 
o Withdrawal by the company of a license application submission if related to safety or 
efficacy; 
o Dates of launch in each country when known; 
o Dates when the marketing authorization has been revoked/withdraw or suspended by a 
RA or voluntarily by the MAH;  
o Invented name(s).  
 Update of Regulatory Authority or MAH Actions Taken for safety reasons - in this section the 
actions taken by the regulatory authorities or by the MAH are described. These actions include: 
o Marketing authorization withdrawal or suspension  
o Failure to obtain a marketing authorization renewal 
o Restrictions on distribution 
o Clinical trial suspension 
o Dosage modification 
o Changes in target population or indications 
o Changes in the formulation  
o Urgent safety restrictions  
 Changes in the reference safety information: In this section, any change in the company core 
safety information (CCSI), made during the period covered by the report, should be clearly 
described.  
 Patient exposure: an estimation of patient exposure to the medicine and the method used to 
estimate that exposure should be provided. If it’s not possible to estimate the number of patients 
then other measures of exposure, such numbers of prescriptions, number of dosage units or 
patient-days are considered acceptable. 
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 Presentation of Individual Case Histories: In this section the cases are presented as line listings. In 
this list must be included: 
o All serious reactions; and no-serious unlisted reactions, from spontaneous notifications; 
o All serious reactions (attributable to drug by either investigator or sponsor), available from 
studies or named-patient ("compassionate") use; 
o All serious reactions, and non-serious unlisted reactions, from the literature; 
o All serious reactions from regulatory authorities. 
 Line-listings:  
o All serious adverse reactions and non-serious unlisted adverse reactions from 
spontaneous reporting; 
o All serious adverse reactions available form post-authorization safety studies and other 
studies or named/compassionate use; 
o All serious adverse reactions, and non-serious unlisted adverse reactions from the 
literature; 
o All serious adverse reactions transmitted to the Marketing Authorization Holder by 
worldwide regulatory authorities. 
 Summary tabulation: For each line listings there is a summary tabulation, usually it is separated for 
serious reactions and for non-serious reactions, for listed and unlisted reactions. 
 MAH’s Analysis of Individual Case Histories: The MAH may want to comment an individual case, to 
discuss any safety concern. 
 Studies: In this section, the MAH should describe the studies where any safety information was 
collected and with potential impact for the safety profile of the medicine. It may contain 
completed studies, studies specifically planned or in progress, and they may be non-clinical, clinical 
and epidemiological studies. Examples:  
o Newly analyzed company-sponsored studies; 
o Targeted new safety studies planned, initiated or continuing during the reporting period; 
o Published safety studies. 
 Other Information: it may contain Efficacy-Related Information, where a lack of efficacy may 
represent a serious threat to the treated population. It may also contain Late-Breaking 
Information, which represents important information received after the data lock point. Overall 
Safety Evaluation: In this section there should be an Overall Safety Evaluation, where the MAH 
evaluates the safety information collected during the period of the report. Concise analysis of the 
data presented and assessment of the data collected during the period.  
 Conclusion: It should indicate which information does not fit the previous cumulative experience 
and specify and justify any action recommended or initiated. Most important, this section should 
address the overall risk-benefit balance in the context of the data presented in the PSUR and 
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indicate which data and results are not in accordance with the previous cumulative experience, it 
should also specify and justify any safety action recommended or initiated. 
New legislation – the impact in Periodic Reporting  
 
With the new legislation the format and content of these reports have been changed. Nevertheless, until 
January 2013 it was possible to submit periodic reports with the new or with the old format. 
Since all suspected adverse reaction data is directly summited to Eudravigilance database, the scope of 
PSUR has changed to an analysis of the risk-benefit balance of a medicine rather than just a list of all 
individual case safety reports that are already submitted to Eudravigilance, avoiding this way the 
duplication of efforts. Therefore the main goal of PSUR, as stated in Directive 2010/84/EC, is to make a 
comprehensive and critical analysis of the risk-benefit balance of the medicinal product taking into account 
new or emerging information on the context of cumulative information on risks and benefits (61). Therefore 
PSURs should be linked to the risk management system for newly authorized medicinal products and these 
should be proportional to the risks posed by medicinal products. The routine reporting won’t be necessary 
for generic medicinal products, for medicinal products containing an active substance for which well-
established medicinal use has been demonstrated under the Directive 2001/83/EC, for homeopathic 
medicinal products and for traditional-use registered medicinal products (31). However at the request of a 
competent authority, the MAH should submit a periodic safety reporting for products that don’t require the 
submission of these reports, due to concerns relating to pharmacovigilance data or lack of safety 
information. (31) 
To avoid duplication of effort and optimize the resources used in the evaluation of PSURs, the data lock 
point and frequency of submission of these reports, for different medicinal products containing the same 
active substance or combination of active substances has been harmonized to allow a single assessment of 
PSURs in the EU, for centralized and nationally approved medicinal products, in more than one MS (61). This 
single assessment allows the evaluation of all available safety data on the benefits and risks of an active 
substance or combination of substances.  
A list of the reference dates and frequency of submission of PSURs is already available,  it contains the 
harmonized data lock point for PSURs with the same active substance and combination of substances (61).  
 
New structure of PSUR 
 
The required format and content of PSURs in the EU are based on those for the Periodic Benefit Risk 
Evaluation Report (61).  
The new format has 3 Parts: the first one is the title page, the second the executive summary and the third 
is the table of contents. In this last part, the information about the safety profile and all relevant 
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information about the clinical trials performed after the product authorization for another indication or 
population is described. It is also important to provide data summaries on the benefits and risks of the 
medicinal product.  
 
 
6.2.4 Safety Variations (Type II safety variations) and urgent safety restrictions  
 
Once a marketing authorization has been granted for a Medicinal Product, safety signals may arise which 
might have a serious impact on Public Health. Depending on the nature of the risk and the impact in Public 
Health, a range of regulatory actions can be taken.  
Among the regulatory actions that can be engaged, it is possible to introduce provisional changes to the 
product information through an urgent 24 hour ”Urgent Safety Restriction procedure”, in order to restrict 
the use or to introduce warnings or precautions for the safe use of the medicinal product. This regulatory 
action may be started by the MAH on its own initiative or by the regulatory authorities and, in the case of 
centralized marketing authorizations, the Commission. (62) 
A document containing the plan on the safety concerns identified is circulated through the EU National 
Competent Authorities for comments and then decided centrally at the European Commission (63).   
Types of variations in medicinal product authorization information: 
 Minor variations of Type IA 
 Minor variations of Type IB 
 Major variations of Type II 
 Extensions  
The minor variations of type IA and IB do not represent any safety concern, those are not analyzed and 
approved in DGRM, and therefore are not in the scope of the present document.  
A major safety variation is contained in the group of type II variation; it does not represent an extension and 
it has a significant impact on the Quality, Safety or Efficacy of a medicinal product. At DRGM, the variations 
analyzed are exclusively for safety concerns, and those usually reflect major changes in the safety profile of 
a medicinal product. The safety type II variations are a safety measure that provides an update to the 
information contained on the SmPC and PL for medicinal products for which a potential safety issue has 
been identified (62).  To this end, Infarmed and more precisely DGRM notify the MAHs of these medicinal 
products by letter to submit the respective application for a Type II Safety Variation. The communication 
between DGRM and each MAH and the submission of the necessary documents is done through the 
electronic submission program for Type II Safety variations requested by Infarmed for the medicinal 
products for which MA was obtained by national procedure. 
However certain changes to a marketing authorization that fundamentally alter the terms of this marketing 
authorization cannot be granted following a variation procedure, and therefore have to be submitted as an 
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extension application. These changes are to be submitted as an extension application and are listed in 
Annex I of the Variations Regulation. (64) (62) 
The following situations, listed in Annex I, are the main categories of changes requiring an extension 
application: 
 changes to the active substance(s); 
 changes to the strength, pharmaceutical form and route of administration; 
 other changes specific to veterinary medicinal products to be administered to food-producing 
animals or change or addition of target species. 
The deadlines for the submission and evaluation of the safety variations will depend on the urgency and 
potential public health impact of the safety issue. Therefore, the CA should establish deadlines that are 
suitable for that matter, and will liaise with Marketing Authorization Holders regarding the appropriate 
deadline, as required. Failure of Marketing Authorization Holders to submit the variation application within 
the deadline may be considered as non-compliance. (65) 
 
 
6.2.5 Rapid alert and Non-urgent information system 
 
The CA and the Agency have a communication system to exchange information. To support rapid 
notification of safety concerns and therefore take appropriate action towards the minimization or 
resolution of a certain issue, the CA, the Agency and the EC operate a Rapid Alert (RA) and Non-urgent 
Information System (NUI). This type of communication system may be initiated by one of the Competent 
Authorities of Member States or by the Agency. (38) 
The pharmacovigilance data related to medicinal products that must be shared with urgency should be 
transmitted through a Rapid Alert between the CA, the Agency and the EC. The information transmitted 
with this level of urgency indicates that action may be needed urgently in order to protect public health. 
(38) 
A RA should be used when a MS or the Agency has a safety concern that has a major impact on the known 
risk-benefit balance of a medicinal product and it considers that prompt action should be taken and that it 
should be communicated to the Healthcare Professionals/the general public (38). Responses to an RA 
should compiled by the initiator and then sent to all Member States, the Agency, the EC and to the 
Rapporteur in case of a centralized product, no later than one week after the receipt of the RA, unless 
otherwise specified (38). According with volume 9A, this information usually refers to: 
 A urgent safety restriction, suspension, revocation or withdrawal of the marketing authorization, 
recall or the suspension of marketing and/or use of a medicinal product; 
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 Action for human blood- and plasma-derived medicinal products following occurrence of vCJD 
(variant Creutzfeldt-Jackob disease) in a blood donor (with specification of batches on the market 
as well as expired batches); 
 Important changes in the SmPC: 
o Introduction of new contraindications; 
o Introduction of new warnings; 
o Reduction in the recommended dose; 
o Restriction of the indications; 
o Restrictions in the availability of a medicinal product; 
 Need to inform Healthcare Professionals or Patients about an identified risk without delay.  
It can be send in other situations such if the reporting rate of certain expected serious reaction increases or 
suggest greater severity. (38) 
If the information does not fit the criteria for a RA, then NUI should be used. Usually it is used to exchange 
emerging pharmacovigilance information at an early stage, such as a new safety signal or an update status 
of a regulatory action, or just a request for information. (38) 
The timeline for response to a NUI is established by the initiator which is also responsible for the 
compilation of all responses and circulation of this information to all MS, the EC and the Agency. (38) 
At DGRM, the NUIs are received and then distributed according with the medicinal product’s CFT 
(classificação farmacoterapêutica). The majority of NUIs are sent by other regulatory authorities or by the 
Agency. The information is collected, organized and then analyzed by the DGRM’s director to be sent to the 
initiator.  
The process may be started by Portugal, if there’s a detection of a safety signal or any safety concern that 
requires an urgent measure, towards a medicinal product or group of substances, such as suspension or 
revocation of a marketing authorization. The document which contains an explanation of the safety concern 
is inserted in EPITT and then sent through the All Human RA email list to all MS, the Agency and EC. If the 
document requires a reply, then the DGRM has to receive and compile every response into a single 
document, which after Directorate validation has to be inserted into EPITT. The subject under debate in the 
NUI or RA has to be discussed in the PRAC, to assess if any measures are necessary to protect the public 
health.  
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6.3 Safety Monitoring of Medicines  
 
As stated in the legislation each Member State should have a system for the collection of spontaneous 
suspected adverse reaction from healthcare professionals, and since July 2012 also from 
patients/consumers, although it was already possible but only with a medical confirmation. (66) 
With the new legislation (July 2012) the definition of adverse reaction changed, and now it covers more 
scenarios for the event of an AR. According to the Directive 2010/84/EC, the definition of adverse reaction 
is a response to a medicinal product that is noxious and unintended and it includes the use of the medicine 
within the terms of the marketing authorization and also outside the terms of marketing authorization, 
which includes overdose, off-label use, misuse, and abuse and medication errors. Occupational is also 
considered as an adverse reaction and it refers to the exposure to a medicinal product as a result of one’s 
professional or non-professional occupation. (66) 
A suspected adverse drug reaction may be reported by a healthcare professional by various ways, such as 
writing, by telephone, or electronically. Healthcare professionals may report directly to DRGM or to the 
Regional Units and directly to MAH. When a reporter notifies on its own initiative, it is called a spontaneous 
report and it is an unsolicited communication by a healthcare professional or by a consumer to a competent 
authority or to a MAH. (66) 
On the other hand a notification may also be solicited, and it is called solicited report, these are derived 
from organized data collection systems, which may be clinical studies, non-interventional studies, post-
approval named-patient programs, registries, surveys or compassionate use. (66) 
A report that arises from worldwide literature may be a spontaneous one or it may result from a non-
interventional study, nevertheless the medical and scientific literature is a source of safety information 
about the medicinal product that allows marketing authorization holders and competent authorities to 
monitor the safety profile of a medicine and calculate its benefit/risk balance. Therefore MAHs should 
perform a systemic literature review of widely used reference databases, no less than once a week. 
However there are a few situations where a MAH does not have to report a literature case as an ICSR if 
another company’s brand is explicitly the suspected medicinal product in the article, or if the adverse 
reaction occurred in a country where the MAH doesn’t have a marketing authorization or has but it’s not 
commercialized. (66) 
It is important to verify if all the necessary elements are present, since the notification has to have 
minimum information to be considered valid. Therefore the report should include at least one identifiable 
reporter, one single identifiable patient, one or more reaction /event and one or more suspected drug(s). 
The patient may be identified by initials, patient number, and date of birth, age, age group, or sex. The 
reporter (primary source) may be identified by name or initials, address or qualification. It is also important 
that any contact detail is available. It is also mandatory the notification has at least one suspected active 
substance/medicinal product and at least one suspected adverse reaction. In the absence of one of these 
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four elements the ICSR is considered invalid and it should be reported, however efforts must be made to 
obtain the missing information, nevertheless, the marketing authorization holder should keep these cases 
in its database. (67) 
All the serious adverse reactions, even if they are already described should be reported by MAH within 15 
days from the receipt of the information containing the minimum criteria for reporting an ICSR. The criteria 
for seriousness are (67):  
o Death 
o Life threatening 
o Involved or prolonged inpatient hospitalization 
o Involved persistence or significant disability or incapacity 
o Congenital abnormality  
o Other (medically significant) 
Besides the serious reactions, also the non-serious should be reported within the period of 90 days from the 
receipt of minimum information for reporting (66) 
There are also several rules for reporting in special situations:  
 Use of a medicinal product during pregnancy or breastfeeding: these cases should be followed 
during the pregnancy and after, during the development of the child. Not all exposures during 
pregnancy should be reported to competent authorities as ICSR, when the pregnancy has a normal 
outcome, without future consequences for the child, it should only be described in the periodic 
safety report(66). However, these cases have to be reported, if the MAH stated it in the risk 
management plan or if the DGRM demands so.  (66) 
 Use of the product in a pediatric population: in this case, when a medicinal product is used by this 
population is important that the company keeps all the records about the case including follow-ups 
to describe in the periodic safety report, however if no ADR occurred then it does not qualify for 
ICSR and it should not be reported to the DGRM or to Eudravigilance. (66) 
 Reports of overdose, abuse, off-label use, misuse, medication error or occupational exposure: if 
no adverse reaction occurred in these situations, then those should not be reported to the DGRM, 
however those should be described in the periodic safety report. However, in the case of a serious 
safety issue that has impact in the benefit-risk balance of the medicinal product, it should be 
notified to DGRM. (66) 
 Lack of therapeutic efficacy: lack of therapeutic efficacy normally should not be reported, but 
when a lack of efficacy is verified with medicinal products used in critical conditions or for the 
treatment of life-threatening diseases, vaccines and contraceptives, it should be reported on an 
expedited manner, within 15 days after the receipt of the information on the case. (66) 
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When one of the previously described reports arrives at DRGM, if the only adverse reaction codified is 
incorrect use or other code that describes the use outside the terms of marketing authorization, a 
pharmacovigilance technician send an information request (via email) to the marketing authorization holder 
to nullify the case in its database.  
 
6.3.1 Electronic transmission  
 
Most of ICSR are sent electronically to DGRM by the MAH. The mandatory status for electronic transmission 
of ICSR was stated in the Regulation No. 726/2004 and Directive 2001/83/EC. The data elements for 
transmission of ICSR are described in the ICH guideline E2B: Data Elements for transmission of individual 
case safety reports.  In electronic transmission, each case has specific number that identifies it, a WWID 
(worldwide identifier). In electronic transmission the WWID is the case number, this is a unique number 
that is the same for follow-ups of a single case. This belongs to the section: A. Administrative and 
Identification Information, along with the primary source(s) of information and information on the sender 
and receiver of the case safety report. Besides the administrative information, there is another section: B.  
Information on the case, which has the patient characteristics, reaction(s)/event(s), results of tests and 
procedures relevant to the investigation of the patient, drug(s) information and narrative case summary 
and further information. This guideline states what should be present in each section and how each field 
should be filled. Each section is identified by a letter, followed by numbers, such as follows: A.1.10.1. (68) 
What is evaluated in each sections and how each should be filled is discuss ahead in this chapter. 
 
6.3.2 DGRM ADR database – SVIG  
 
DGRM has a database for the management and storage of ADRs called SVIG and it allows the electronic 
reception or manual insertion of cases.   
Each section of this database is based on the E2B ICH Guideline. The SVIG sections (most important sections 
for the validation and quality of the case) are:  
 Administrative information: contains the WWID number, the safety number and the Infarmed’s 
number. It also contains the dates of the initial and most recent reception of information by the 
primary source and in the sector. It also contains the type of report (spontaneous, study or 
another), the country where the adverse relation occurred, the country of the reporter, the 
information if the case received medical confirmation and the seriousness of the case, including 
the seriousness criteria.  
 Annexes: In this section the documents that accompanied the notification are attached and the list 
of similar cases and duplicate cases is also constructed.  
 Sender: The information about the sender is described in this section, such as the type of sender 
(pharmaceutical company, CA, health professional, etc.). The sender’s identity, name and address 
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are also presented in this section. Usually the sender is the secondary source, which received the 
information about the case from the primary sender, the reporter.  
 Reporter (primary source): The reporter is the person that collects and sends all the information 
about the case directly to DGRM, regional units or to the marketing authorization holder.  A 
reporter may be identified by the name or initials, the address or the country. The qualification is a 
mandatory section for electronic transmission; among the options are physician, nurse, 
pharmacist, other healthcare professional, lawyer, consumer, etc.  
 Case data: The case data contains information about the patient, such as the name initials, the age, 
date of birth, weigh, height, gender, etc. In another section it contains the clinical history, which 
should be used to list all procedures and medical conditions that begun before the adverse 
reaction. These medical conditions may be chronic and present at the time of the adverse reaction. 
The pharmacological history is also present in this section and it should be filled with the 
information about the medicinal products that the patient used during a certain period of time 
before the adverse reaction. The final part of the case data are the tests performed to the patient, 
those are performed at the time of the adverse event or after, as follow up measure.  
 Patient Death: This section is only filled if the patient died; it contains the date and the cause of 
death.  
 Parent information: This is used for a parent-child/fetus report, where the parent had no 
reaction/event. It contains the clinical and pharmacological information about the parent.  
 ADR information: This contains all the information about the adverse reaction(s), including the 
information about the dates and duration of the adverse reaction. All adverse reactions should be 
reported in MedDRA.  
 Suspected medicinal product(s) information: The suspected medicinal products are listed in this 
section, and it contains information of the treatment dates, the medicinal product’s allotment, 
measure taken towards the medicinal product (dose augmentation, unknown, unchanged dose, 
not applicable, dose reduction and drug suspension), it also contains the result of the re-exposition 
to the medicinal product.  
 Narrative:  The case is described with all the details in this section and it is written in a text 
manner. The follow-up information is also contained in this section with the identification of it and 
the date it was received by the company.  
 
6.3.3 Reception, validation and management of all notification sent by MAH  
 
Before its submission to DGRM and in order to ensure that the minimum information required is included in 
the report, the MAH is expected to validate all adverse reactions reported. However even with the cases’ 
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validation by the marketing authorization holder, the pharmacovigilance technicians of DRGM also validate 
all the expedited cases that arrive through CIOMS I or electronically.  
When a MAH receives a spontaneous report of an ADR, that qualifies for an expedited report, from a 
healthcare professional or other source, it should be reported to DGRM. It is also possible that a healthcare 
professional reports a reaction directly to the competent authorities. If the MAH becomes aware of this 
situation, he should report the case and inform the DGRM that it is a duplicate.  
It is also possible to monitor for ADRs through organized data collection systems, such as post-authorization 
studies, patient registries, surveys of patients or healthcare providers, etc.  
The transmission of these adverse reactions is done electronically, save in exceptional circumstances, for all 
authorized medicinal products in the EU. However, if a MAH is not already in electronic transmission or if it 
is not possible to send a notification electronically then, the report may be send in CIOMS I format in the 
case of serious reactions, or CIOMS II, in the case of a non-serious reaction.  The CIOMS I form has been a 
widely accepted standard for expedited adverse event reporting. Usually only CIOMS I is received since the 
most important notification are the ones that refer to serious reactions and/or non-described. This may be 
send to DRGM by email, fax or post-mail, with the same reporting timelines.  
 The CIOMS I (69) is divided into 4 groups: the first one refers to the reaction information. It 
contains the information that identifies the patient, the description of the reaction, with the codification of 
which reaction in MedDRA, the criteria for seriousness and the narrative, in which the event is described 
with detail.  
 
Figure 8 - CIOMS I form, section I Reaction Information.  
 
The second section contains the suspected drug(s) information, where the name of the drug is present 
(brand name or, when not possible to obtain this information, the active substance), posology and the 
result of de-challenge and re-challenge.  
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Figure 9 - CIOMS I form, section II Suspected drug information.  
 
The section III describes the concomitant drug therapy (drug(s) that was/were being concomitantly 
administrated with the suspected drug) and the clinical history, which includes all the medical procedures 
and history of diseases that had or has but are not a result of an adverse reaction to the product.  
 
 
 
Figure 10 - CIOMS I form, section III concomitant drug(s) and history.  
 
Finally, the IV section is used to add information about the manufacturer; it is many times the same person 
that sent the case to DGRM, it also contains the date in which the manufacturer received the information 
about the case and the date in which the report is finished. The source or the origin of the report is 
identified, and it can be a literature report, spontaneous or a study. The report type is also selected 
between initial or follow up. There are marketing authorization holders that in this section also give 
information about the primary source (reporter) of the report.  
 
 
Figure 11 - CIOMS I form, section IV manufacturer information.  
 
When a case is received through a CIOMS I form, it has to be manually inserted into SVIG. This database 
generates a number, that is the same in case of follow up, and thus the new information is inserted in the 
same case.  
In the case of electronic transmission, it may be in two ways, from the MAH database and/or from DRGM to 
MAH. The MAH inserts the information into his database then it is transmitted via XML and sent to SVIG. An 
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acknowledgement report is generated from this operation to inform the MAH that the information was well 
received, received with an error or non-received. 
As described previously, after the arrival of the case, there’s the validation step, which consists in the 
verification of the administrative and minimum information with the aim to verify if it is present and 
properly filled.  
If the minimum criteria is not present, then a solicitation of information to the MAH should be performed, 
to whom is given a specific date to send the information. This request is also made for another type of 
information, to enhance the quality of the notification and to simplify the signal detection. When the 
requested information arrives, it is verified again. If the information is in accordance with the requirements, 
then a duplicate search is made and it is registered as a new case, a follow-up or a duplicate. A duplicate 
search is made in SVIG, and it is made using the patient initials, age, date of birth, adverse reactions and/or 
by suspected drug. This search is due to the fact that some ICSRs, especially those which are serious, may 
be reported to DGRM from more than one source, such as the MAH or a healthcare professional. Each 
duplicate should be market as inactive, and the case that is not a duplicate should remain active.  
Each case may receive various follow-ups, these are sent when new important information about the case is 
obtained and it is important for its scientific evaluation. When a new case is received and has the same 
WWID of another case, it means that this is a follow-up of a previous case and therefore, to the initial case 
is added new information. It is important to verify if the dates are correct, since the section with the most 
recent date of reception has to be different from the date of initial reception of the case by the company 
and by the sector. When a follow-up is received through CIOMS I form, in order to identify the initial case of 
the follow-up, a brief verification and comparison of the data between the two cases should be performed.  
There are three scenarios that must be considered when managing case reports and duplicates. The first 
scenario is two duplicated cases that were directly reported to DGRM by healthcare professionals - in this 
situation the case that should be market as the inactive is the one that has a posterior date of reception in 
the sector. All the relevant information in the inactive case should be added to the active case.  
In the scenario of a case that was sent a healthcare professional and a MAH, the active case is the one that 
was sent by the healthcare professional and the other case, sent by the MAH is inactivated. All the relevant 
information in the case sent by a marketing authorization holder should be added to the active case.  
When the same case is sent by two marketing authorization holders, the active case is the one that has the 
oldest date of reception in the sector and the other should be inactivated.  
After these procedures a technical analysis of the case should be performed.  
 
Technical validation of the cases 
 
After the validation of the ICSR, the pharmacovigilance technician analyzes the information contained in 
SVIG. It has to be kept in mind that is not necessary to fill every data element of every section, since it is 
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almost impossible to do, but it is necessary to fill the minimum data elements so that the report can be 
electronically transmitted and validated.  
 
 
Analysis of each section of the ICSR  
 
Administrative section (E2B A.1) 
The analysis starts with the verification of the WWID and the safety ID, in order to verify if those are well 
constructed. It also important to verify the reception dates. 
 
In SVIG database there are four data fields that have to be filled so the case can be validated:   
 Date of initial reception by the company  
 Date of the initial reception in the sector 
 Date of most recent reception by the company  
 Date of the most recent reception in the sector 
 
For an initial case: 
 Date of initial reception by the company is the same as the date of most recent reception by the 
company; 
 Date of the initial reception in the sector is the same as the date of the most recent reception in 
the sector.  
 
In the case of a non-valid ICSR, the “Date of initial reception by the company” should be the date of receipt 
of the initial non-valid ICSR, although it can only be reported when containing the minimum criteria, 
therefore the element data “Date of the initial reception in the sector” is the same as “Date of the most 
recent reception in the sector”.  
  
For a Follow-up case: 
 Date of initial reception by the company is previous to the date of most recent reception by the 
company; 
 Date of the initial reception in the sector is previous to the Date of the most recent reception in the 
sector. 
 
The data element “type of report” (E2B A.1.4) is also listed in the administrative section, it can be 
spontaneous, if the case arises from a spontaneous observation, it can be defined as a study, if it arises 
from an observational study or it may be codified as other, if it arises from a literature report and it is 
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unclear if it arises from a spontaneous observation or from a study (68). This is an E2B field and it is very 
important to be correct, if not, then an information request should be send to the MAH to correct it.  
Another E2B data element is the reporter country (E2B A.1.1), this is the basis for the construction of the  
WWID, in other words, the reporter country sets the first part of the WWID code, for example, when the 
reporter  is form Portugal, then the WWID will begin with PT.  
When a report is nullified, it is presented in the A.1.13 data element - report nullification. This item should 
be used to indicate that a previously transmitted report should be considered completely void. An 
explanation for the nullification should be provided and only the sender can nullify the case, and once it has 
been nullified, it cannot be reactivated. This is used when a case has been identified as a duplicate of 
another individual case, previously submitted by the same organization. (68)  
When a wrong WWI was accidently used and does not refer to an existing case, it should be nullified and 
other case with the correct WWID should be send. However if the WWID refers to an existing case, the 
report should not be nullified but rather the marketing authorization should submit a follow up to correct 
the information previously sent. A new ICSR should be created and submitted with the correct WWID. (68) 
A case should also be nullified when certain elements are not consistent, for instance, when the patient 
took the suspected medicinal product after the reaction onset or did not took the medicinal product at all. 
It also qualifies for nullification if the reporter confirms that the adverse reaction did not occur to the 
patient or there is no valid patient for the individual case (66).In these cases the minimum criteria for 
reporting is no longer met and therefore the case is not an ICSR.  
In the section of administrative information, it also important to verify if the case is serious and the criteria 
for seriousness (death, life threatening, hospitalization, persistent or significant incapacity, congenital 
anomaly/birth defect or other medically important condition) (67). 
If the case resulted in death then the section “patient death” should be filled if there is any information 
regarding the cause of death and the results of the autopsy and in this report, at least one reaction should 
have the outcome death (70).  
 
Annexes section  
The WWID of each duplicate or related case should be listed in the annexes section and in the case of the 
duplicate cases, each one of these should have the WWID of the active case in the section for the authority 
comments.  
 
Sender section  
This section contains the information about the case sender that may not be the MAH, but someone 
responsible for the electronic transmission.  
The type  of sender (ex: pharmaceutical company, regulatory authority or healthcare professional) has to be 
filled so the case can be validated (68).  
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Reporter section  
First it is important to verify which type of reporter reported the case or in other words the reporter’s 
qualification (physician, pharmacist, dentist, other healthcare professional, consumer, lawyer or other non-
healthcare professional) (68). 
In the case of a literature report, the literature reference (E2B A.2.2) must be filled according to Vancouver 
guidelines (66). 
If in the “administrative section”, the type of report is study, then in the “reporter section” other studies or 
individual patient use programs should be selected, if clinical trial is selected, then the case should not be 
analyzed and validated by DGRM, since SUSAR’s are under the responsibility of another directorate at 
INFARMED. The name of the study should be filled (E2B A.2.3.1). 
 
Case data  
In the “section case data” there are four sub-sections: patient characteristics, relevant medical history, 
relevant past drug history and the tests performed to the patient.  
Sub-section: patient characteristics 
One of the following data elements have to be filled in order to consider the report valid (68): 
- Patient initials, for privacy agreements, this data element may be filled with “privacy” instead of 
the patient’s initials, or with nothing, when the initials are unknown; 
- The patient gender;  
- Date of birth, age, or age group of the patient.  
If none of these elements are filled then an information request has to be sent to the MAH, and if he does 
not have information about any of these elements then the case has to be nullified since it has not the 
minimum criteria for reporting.  
In the case of a fetal demise or early spontaneous abortion, only a parent report is applicable, however if 
both parent and the child/fetus had an adverse event, then two reports should be prepared and linked by 
using the related cases sub-section in each of the reports. When only the child/fetus had an adverse 
reaction, the information provided in this sub-section applies to the child/fetus and characteristics 
concerning the parent, who was the source of exposure to the drug, should be provided in section 
Progenitor information. This is a parent-child/fetus report and if only the parent had an adverse reaction, 
then only one report should be submitted, with the information about the mother and the gestation time. 
When the reaction(s) occurs in the fetus, the data element “Gestation period when reaction/event was 
observed in the fetus” should be used. (68) (66) 
If the patient (child/fetus) and parent sections are not properly filled with the right information, an 
information request should be sent the marketing authorization holder requesting to correct the data 
elements and send a follow up. (68) (66) 
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Besides the data elements described for this sub-section, there is also other information that can be 
provided to improve the quality of the case and facilitate its analysis, and those are the patient height, 
weight and last menstrual period date. (68) (66) 
 
Sub-section relevant clinical history 
This section may or may not be filled with the patient clinical history; however if it is described in the 
narrative then it should be listed in this section. It contains all the previous medical conditions and 
procedures; it should also include any current health condition that has started previously to the adverse 
reaction.  (68) 
The data elements listed in this sub-section have to be provided according to the last version of the 
MedDRA terms.  
 
Sub-section relevant past drug history 
This section should only include medication previously taken and not those taken concomitantly or that 
may be involved, or are potentially involved in the current adverse reaction(s) event(s). (68) 
 
Tests performed to the patient 
All the tests performed to the patient should be listed in this section and coded in MedDRA. (68) 
 
Patient Death 
This section should only be filled if the patient died, therefore the seriousness criteria and the outcome of 
at least one of the adverse reactions should be death, in order to validated the case (68), (70). 
The information about the date of death (E2B B.1.9.1) and/or cause of death (E2B B.1.9.2) should be 
present (68). If an autopsy was performed and the cause of death was determined, it can be referred in this 
section.   
 
Parent information 
This section should only be filled if the report is a parent-child/fetus report (the parent had no adverse 
reaction(s)) and it should contain the parent data, such as the parent’s age, parent’s birth date or parent’s 
gender. This section should be used in the case of a parent-child/fetus report where the parent had no 
reaction/event. It can also contain the height, weight or the last menstrual period date of the parent. (68) 
 
ADR information 
This section should contain at least one valid adverse reaction with the correspondent outcome. The 
outcome can be chosen between the following: recovered/resolved; recovering/resolving; not 
recovered/not resolved; recovered/resolved with sequel; fatal or unknown. The outcome must be in 
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accordance with what is described in the narrative and with the seriousness criteria. It is also important to 
verify the date of adverse reaction onset to confirm that it happen after the intake of the suspected 
medicinal product.  (68) 
Only the MedDRA Lowest Level Term (LLT) most closely corresponding to the reaction/event as reported by 
the primary source should be provided (68). 
During the reaction codification the MedDRA Term Selection: points to consider (bases on the last version) 
should be consulted and analyzed. It contains guidance on how to codify each adverse reaction in each 
situation.  
There are a few situations that are quite common during the codification of an adverse reaction. For 
example death can only be codified as an adverse reaction if there is no other adverse reaction or 
information of what caused death to the patient.  
When the primary source reports the definitive diagnosis along with the symptoms of that diagnosis, the 
preferred term to codify is the definitive diagnosis. When a provisory diagnosis is given with the symptoms, 
then all of these terms should be codified and reported. (70) 
When lack of efficacy is reported, it is important to code the terms “lack of effect” and although it is not 
always an adverse reaction, it is important to record modification of effect (e.g. increased, prolonged) (70). 
There are also a few situations that are not to be reported, however some marketing authorization holders 
report those due to intern arrangements and company policies. For instance, the use of a medicinal product 
during pregnancy without any adverse reaction does not qualify for reporting, however in the event of 
reporting then it should be coded as pregnancy and no adverse effect.  (70) 
There are many other situations that require special attention in order to improve the quality of the cases 
and the constant enhancement of the national pharmacovigilance system.  
 
Suspected medicinal product(s) information 
In this section there is a list of the suspected and concomitant medicinal products and the involvement of 
them in the adverse reaction. The characterization of the involvement of the drug may be: suspected, 
concomitant or interacting (68).  
The medicinal products may be identified by proprietary medicinal product name, active substance or DCI 
(Denominação Comum Internacional). When possible a medicinal product should always be coded with the 
brand name. It is very important to verify what type of drug it is and how is it coded. If it is wrongly codified 
then an information request should be sent to MAH in order to correct it.  
The therapeutic class of the medicinal product should not be used to codify a medical product, for example, 
when Anti-Histaminic is reported as a suspected medicinal product, then it should be correct into the exact 
name of the medicinal product.  
The action taken towards the medicinal product is also a very important sub-section to fill, it can be: drug 
withdraw, dose reduced, dose increased, dose not changed, unknown and not applicable. It is also very 
important to known the result of the re-challenge (68).  
Internship Report in Pharmacovigilance 
 
64 
 
In this section the reporter may add a considerable amount of information about the dates and the dosage 
regime of the medicinal product, which facilitates the pharmaceutical and clinical analysis of the case.  
The relation between the suspected(s) drug(s) is reflected in this section, this relation is given by the 
reporter and by the marketing authorization holder.   
 
 
Narrative  
The narrative should contain the following information and, in preference, according to this order:  
- The summary of the case with the important data and minimum criteria; 
- Description of the beginning and development of the adverse reaction; 
- Relation between the suspected medicinal product and the adverse reaction, with the respective 
dates; 
- Treatment and evolution of the adverse reaction;  
- Any other relevant information. 
In case of a follow up case, the information should be added to the narrative and clearly identified as a 
follow up with the respective date.  
 
 
6.3.4 Suspected adverse reaction reported by a healthcare professional and consumers  
 
For reports that arise directly from healthcare professionals the analysis of each case is more or less the 
same as the one described in the previous chapter. Each report may arrive in paper, fax, mail, email, by 
phone call or directly through the Portal RAM.  
The form that can be used by healthcare professionals to report an ADR (71), has the following 6 sections:  
 
 
Figure 12 - A: Adverse reaction  
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Figure 13 - B: Suspect Medicinal product(s)  
 
 
Figure 14 - C: Concomitant medication  
 
 
Figure 15 - D: Patient 
 
 
Figure 16 - E: Healthcare Professional  
 
 
Figure 17 - F: Comments (narrative)  
 
For consumers, the report form (72) is similar, but with simpler language for a better understanding. When 
a case is written in one of these forms it has to be manually introduced into the SVIG, and the codification 
has to be done by the technicians at DGRM or Regional Units, because most of the times an adverse 
reaction or a previous condition of the patients does not come coded in MedDRA but in common language. 
During the manual insertion of the information, it is normal that certain questions arise. These questions 
should be appointed and asked to the reporter, in order to better understand the case and improve its 
quality.  
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The reports may arrive to DGRM or to one of the 4 regional units. When a case occurred in the continent, 
then it should be analyzed by the regional unit responsible for the specific area, for example, if it happened 
in Faro, it should be analyzed by the South regional unit. When a case arrives from one of the Portuguese 
archipelagos (Azores and Madeira), than it should be analyzed by one of the DGRM technicians, since there 
is no regional unit there.  
As referred previously, the cases may also be directly reported to the web portal (Portal RAM), created due 
to the new pharmacovigilance legislation that allows the patients/consumers to report any adverse reaction 
that occurred in Portugal. This is a platform that allows the collection of information on ADRs. The reporting 
of adverse reactions by health professionals or consumers is essential for the continuous monitoring of the 
safety of medicines. Upon receipt, the information is evaluated by a team of experts in pharmaceutical and 
medical safety of drugs, in order to characterize the probability that the reaction described is due to the 
medication. 
 
 
6.3.5 Causality assessment 
 
The classification used at DGRM is the WHO scale (73): 
 
Definitive – To attribute this category, there has to be a solid clinical evidence or laboratorial modification 
that occurred with a plausible temporal relation and it cannot be explain by any concomitant diseases or 
other medicinal products. If the drug is withdrawn and the adverse reaction stopped, and then if the 
adverse reaction reapers when the medicinal products is reintroduced, the relationship between the 
suspected medicinal product and the adverse reaction is definitive.  
 
Probable – a clinical event or laboratory abnormality with reasonable time relationship to drug intake, the 
reaction was unlikely caused by other conditions or drugs and the evolution of the adverse reaction after 
the suspension of the medicinal product is acceptable.   
 
Possible - a clinical event or laboratory abnormality that occurs in a relationship that is temporally 
acceptable, but can also be explained by other conditions or medicinal products and Information on drug 
withdrawal may be lacking or unclear. 
 
Unlikely – a clinical event or laboratory abnormality that occurs in a relationship that temporally unlikely, 
but not impossible, and the association with other medicinal products or conditions provides a plausible 
explanation.  
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Conditional/Unclassified – To classify this adverse event is necessary more information to properly 
evaluate the case.  
 
Not Classifiable – This is a report that suggests an adverse reaction, but it not possible to establish causality 
because the information is contradictory or is insufficient and it cannot be confirmed.  
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6.4 Articulation between the Directorate of Risk Management for 
Medicines and the Directorate of Inspection and Licensing in quality 
questions  
 
When a suspicion of quality issue is reported to DGRM it must be also sent to Directorate of Inspection and 
Licensing (DIL), which is the responsible directorate for the manufacture compliance and quality alerts. In a 
report with a description of a non-compliance, in which there is no occurrence of ADR, the report is forward 
to the DIL. However, if an adverse reaction is also described in the mentioned report, it should also be 
analyzed by DRGM and by DIL. At DGRM, a pharmaceutical and clinical analysis is performed in relation to 
the adverse reaction. 
 
6.5  Intensive Monitoring of Medicines  
 
The intensive monitoring of medicines is performed when there is a special concern about safety or quality 
of a medicinal product, and it needs to be monitored during a certain period of time. At DGRM this task was 
performed by the drug safety monitoring group and it consists in the analysis of safety data of a certain 
medicinal product.  
For this purpose, the frequency of analysis is determined by the directorate after a meeting with the 
technician responsible for this task. Then a series of listings are requested in order to analyze the safety 
data correspondent to a certain period of time. These listings contain all adverse reactions that occurred 
with the medicinal product under additional monitoring. The output of the list has to be analyzed to 
transform the data contained into a report with important conclusions. If any safety issue arises from the 
listing analysis, this information must be reported and discussed with the Directorate. If the issue is also 
related with a quality issue of the product, it has to be reported to DIL.  
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7. Article in Pharmacovigilance Bulletin  
 
During my internship I had the chance of being co-author, along with Dr.ª Ana Araújo, of an article with the 
title: Nova Legislação de Farmacovigilâcia: Impacto na relação autoridade/notificador. This article focused 
on the relationship between INFARMED and the healthcare professionals/consumers in terms of 
pharmacovigilance. The main discussed topics in the article are:  
 The main objective of the new pharmacovigilance legislation and the reason why it was created; 
 Describe the main modifications from the previous legislation, such as: 
o Greater involvement of patients in the reporting process, since patients may at their own 
initiative report ADRs directly to INFARMED.  
o Possibility of consumers, patients and healthcare professionals report an ADR on Portal 
RAM.  
o Broader definition of ADR, which now includes also, all the ADR that occur outside the 
terms of MA and the medication errors, overdose, misuse, abuse and off label use.  
o Increase of transparency, with the creation of a national portal linked to the European 
Medicines Agency website.  
o Public hearings on the safety of medicines, where besides healthcare professionals and 
the pharmaceutical industry, the general public may also be present.  
o The medicinal products under additional monitoring will be identified, in the SmPCs and 
PL, by a black colored symbol and an explanatory sentence, relevant and standardized in 
order to contextualize the need for additional monitoring for that specific medicinal 
product.  
o Inclusion of a standard text in the SmPC and PL, appealing to the notification of any 
suspected adverse reaction.  
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8. Conclusion  
 
The INFARMED internship was the most rewarding and fantastic experience of my academic life. Therefore 
it can be difficult to translate into words in a comprehensive manner all the knowledge and lessons taken 
from this experience. The opportunity that was given to me, to develop my thesis at DGRM, was very 
productive and flattering. The work environment was very good, which facilitates the learning process and 
development my professional and social skills.  
I took part of different activities, which contributed to my professional growth. To become more 
independent and capable of dealing with responsibilities, I had the help and constant support of my 
colleagues at DGRM.   
It also allowed me to analyse the interactions between a Competent Authority, the healthcare professionals 
and the marketing authorization holders. All my knowledge acquired during the degree in Biomedical 
Sciences and the Master’s Degree in Pharmaceutical Medicine became clearer and easily understood.  
The fact that I spent half of my internship in the risk management team and the other half in the medicines’ 
safety monitoring team, allowed me sufficient time to understand how each of these groups work and what 
type of work is performed by each one.  
I also had the chance to follow the entering into force of the new legislation and the development of the 
new Portal for submission of ICSR by patients and by healthcare professionals, which allowed me to 
understand the foundations of the new legislation. 
This internship allowed me to conclude that the post-authorization stage of a medicinal product is a critical 
phase in terms of safety data collection and public health protection.  
In conclusion, my objectives for the future are the continuous improvement of my skills and acquiring 
knowledge to be able to carry out my work in pharmacovigilance.  
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9. Appendices  
 
9.1 Glossary  
 
Medicinal Product - According to the Directive 2001/83/EC a medicinal product is “any substance or 
combination of substances presented as having properties for treating or preventing disease in human 
beings or any substance or combination of substances which may be used or administered to human beings 
either with a view to restoring, correcting or modifying physiological functions by exerting a 
pharmaceutical, immunological or metabolic action, or to making a medical diagnosis. “ 
 
Individual Case Safety Reports (ICSR) - An ICSR is the format and content for the reporting of adverse 
reaction(s) with a medicinal product that occur in a single patient at a specific point of time. It should 
contain the minimum criteria for reporting, one identifiable reporter, one single identifiable patient, at least 
one suspect adverse reaction and at least one suspected medicinal product. (67) 
 
XML - eXtensible Markup Language (XML) is the adopted standard for the exchange of Safety and 
Acknowledgement Messages in the European Economic Area (EEA). (Note for guidance – EudraVigilance 
Human – Processing of safety messages and individual case safety reports (ICSRs)) (74) 
 
Special situations during reporting of adverse reactions (66): 
a. Overdose  
This refers to the administration of a quantity of a medicinal product given per administration or 
cumulatively, which is above the maximum recommended dose according to the authorized product 
information. Clinical judgment should always be applied.  
b. Off-label use  
This relates to situations where the medicinal product is intentionally used for a medical purpose not in 
accordance with the authorized product information.  
c. Misuse  
This refers to situations where the medicinal product is intentionally and inappropriately used not in 
accordance with the authorized product information.  
d. Abuse  
This corresponds to the persistent or sporadic, intentional excessive use of a medicinal product, which is 
accompanied by harmful physical or psychological effects.  
e. Occupational exposure  
This refers to the exposure to a medicinal product, as a result of one’s professional or non-professional 
occupation. 
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MedDRA - MedDRA stands for Medical Dictionary for Regulatory Activities – this a medical terminology that 
should be used for regulatory documents, to classify adverse event information associated with the use of 
biopharmaceuticals and other medicinal products. This allows the comprehension of each individual case 
safety report and reduction of duplicated work. (75) 
 
EPITT (European Pharmacovigilance Issues Tracking Tool) - Is a web-based system that effectively tracks 
and monitors the safety of medicinal products regardless of their authorization type. The objectives include 
the monitoring of life-cycles of safety signals and safety issues discussed at the level of the 
Pharmacovigilance Working Party (PhVWP) and hereafter the Pharmacovigilance Risk Assessment 
Committee (PRAC), the tracking of the Periodic Safety Update Report (PSUR) cycles’ and timetables' 
assessments performed by the National Competent Authorities (NCA) in the context of the PSUR Work 
Sharing project, and Risk Management activities. (76) 
 
GVP – These documents are a set of orientations created to facilitate the performance of 
pharmacovigilance in the European Union (EU). These guidelines apply to the MAH, to the Agency and to 
competent authorities, and its aim is to provide a more detailed guidance and improve safety for the 
patients by strengthening pharmacovigilance across the EU. (44) 
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